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ABSTRACT 
EFFECTS OF CONJUGATED LINOLEIC ACID (CLA) ON SKELETAL MUSCLE 
METABOLISM 
 
SEPTEMBER 2015 
 
YOO KIM, B.A., KOREA UNIVERSITY, KOREA 
 
M.A., KOREA UNIVERSITY, KOREA 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Yeonhwa Park 
 
 
Although it is well known that increased physical activity can help reduce incidences of 
obesity, physical activity can be influenced by complex issues, making it difficult to use universal 
means to control obesity. Recent discoveries of the effects of exercise at the cellular level opened 
up the unique opportunity to develop compounds with ‘exercise-like’ effects. In fact, CLA has 
been shown to promote voluntary activity and endurance capacity in mice. Thus, the purpose of 
these studies is to determine the mechanisms of conjugated linoleic acid on muscle metabolism 
via the modulation of biochemical events including mitochondrial biogenesis and the alternation 
of fiber composition in skeletal muscle in order to develop preventive strategies for obesity. 
Based on in vitro fundamental mechanism studies, we observed that CLA stimulated 
mitochondrial biogenesis by signaling the up-regulation of peroxisome proliferator-activated 
receptor γ coactivator 1α (PGC-1α) and related biomarkers involved in muscle metabolism. These 
new findings provided the opportunity to consider CLA as a candidate for bioactive compound 
mimicking exercises. We conducted additional animal studies, which were organized into three 
parts. The first part was an adult obesity study with the nescient basic helix loop helix 2 (Nhlh2) 
gene knockout mice, which are the genetically induced inactivity adult-onset obesity model. 
Moreover, the study was designed for childhood obesity with post-weaning Nhlh2 mice under the 
pre-obese state. Lastly, this was an exercise model, which divided normal mice into four groups 
vii 
according to diet and training, such as sedentary or exercise regimes. Consequently, these three 
studies have shown that CLA enhances voluntary activity and endurance capacity. Additionally, 
there were increases of muscle mass and decreases of body fat mass through modulating muscle 
metabolism by stimulating mitochondrial biogenesis, inducing genes of muscle fibers, and 
enhancing lipid metabolism based on the AMP-activated protein kinase (AMPK) signaling 
pathway. Particularly, the PPARδ-mediated pathway plays a central role in overall skeletal 
muscle metabolism. The current results suggest that CLA acts as a potential exercise-mimetic, 
resulting in improved physical activity, which can also support its function of regulating body fat. 
viii 
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CHAPTER 1 
INTRODUCTION 
Around 40-60% of the world population suffers from obesity and related chronic 
diseases including type II diabetes, cardiovascular disease, metabolic syndrome and certain types 
of cancer. Calorie restriction accompanied with physical activity leading to increased energy 
expenditure is elucidated as the most effective strategy to reduce obesity.1,2 Although increased 
physical activity contributes to various health benefits for attenuating an incidence of obesity as 
well as its associated pathologies, complex social, environmental, physiological and 
psychological factors can affect the subject’s physical activity. Thus, it is difficult to simply use 
physical activity as universal means to control obesity. However, over the last decade, a growing 
body of evidence has shed light on the unique importance to intervene and develop drugs or 
dietary components as an exercise mimetic to demonstrate the alteration of molecular targets by 
exercise.3-6 
On a weight basis, skeletal muscle tissue is the largest portion of total body mass in the 
normal human body, excluding obese individuals. Skeletal muscle is one of the most 
metabolically demanding tissues, which accounts for almost half of all energy expenditure, as 
well as three-fourths of all glucose disposal. In addition, skeletal muscle has a unique metabolic 
flexibility in energy metabolism, responding to physiological and pathophysiological conditions. 
Particularly, it is possible for skeletal muscle to selectively use fuel sources such as glycogen, 
glucose and fatty acids for energy production depending on aerobic or anaerobic metabolism in 
response to exercise or chronic contractile activity.7-9 Although skeletal muscle as a whole acts as 
a contributor to glucose and fatty acid metabolism, the composition of fibers in individual muscle 
plays a critical role in muscle energy metabolism. Specifically, the metabolic plasticity of fibers 
in skeletal muscle relies on mitochondrial content and composition. Mitochondrial biogenesis—
which is generally referred to as mitochondrial adaptions responding to external stimuli such as 
2 
exercise—increases mitochondrial volume and changes its composition, contributing to an 
alteration of metabolic preference from glucose to fatty acids.10-12  
Conjugated linoleic acid (CLA) is a mixture of geometric and positional conjugated 
isomers of linoleic acid. The effects of CLA have been previously demonstrated to influence the 
development of cancer and atherosclerosis, in addition to preventing osteoporosis and modulating 
immune responses.13,14 Moreover, CLA has garnered special attention in the last two decades for 
its anti-obesity effects through various mechanisms, such as the regulation of energy and lipid 
metabolism, adipogenesis, inflammation and adipocyte apoptosis.15,16 Furthermore, in animal 
models, it was reported that CLA improved voluntary activity and endurance capacity and 
modulated energy metabolism.17,18 
 Although further studies are needed to demonstrate the role of CLA in skeletal muscle, 
the accumulated evidence to date of increased lean body mass and improved physical activity 
provide clues on how CLA might modulate skeletal muscle metabolism. Thus, we expect that the 
regulating mechanisms of CLA in skeletal muscle can elucidate the preventive effects on obesity 
along with currently known effects on adipose tissue. In addition, we expect that the information 
obtained from the successful completion of this research will expand our understanding of the use 
of bioactive food compounds and physical exercise to control obesity. 
  
3 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Overview of CLA 
 Since the discovery of CLA in beef, it is known that the primary dietary sources of CLA 
are meats and dairy products from ruminants. It is reported that in dairy products, CLA contents 
range between 0.34 and 1.07% of the total fat, and in raw or processed beef range between 0.12 
and 0.68%.19 Although we continuously consume CLA daily in foods originated from ruminant, 
concentrations of CLA in food (less than 10 mg CLA/ g fat) are not substantial.20 The average 
daily CLA intake in the U.S. from food sources is 104-151 mg and 176-212 mg for women and 
men, respectively.21,22  
CLA has two active isomers (cis-9,trans-11 and trans-10,cis-12 isomers), which produce 
different biological effects.14 CLA isomers mostly originate from either biosynthesis or chemical 
synthesis. The cis-9,trans-11 is a natural predominant isomer which accounts for over 80% of 
CLA isomers and is derived from the biohydrogenation of rumen bacteria.23,24 In addition to cis-
9,trans-11, the most notable CLA isomer is the trans-10,cis-12. However, in natural foods the 
amount of trans-10,cis-12 is very low. When chemical synthesis is used, this isomer forms in 
significant amounts.20 Although CLA has at least 28 different isomers, cis-9,trans-11 and trans-
10,cis-12 isomers have demonstrated the most favorable health benefits. Currently, most 
commercial CLA preparations are composed of almost equal amounts of cis-9,trans-11 and trans-
10,cis-12 isomers (also referred to as a CLA mixture or 50:50 mix).  
 Over the last two decades, studies have uncovered some negative health issues of trans 
fat, and it is therefore necessary to define the trans fatty acids in CLA.25 The definition of trans 
fat labeling by U.S. Food and Drug Administration (FDA) is “all unsaturated fatty acids that 
contain one or more isolated double bonds in a trans configuration”.26 This definition means that 
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conjugated linoleic acid (CLA) is ruled out from this regulation to label trans fats, since non-
conjugated trans fatty acids are distinguished from conjugated forms. Further, in July 2008, the 
FDA approved CLA for a GRAS (Generally Recognized as Safe) status for specific food 
categories such as fluid milk, yogurt, meal-replacement shakes, nutritional bars, fruit juices and 
soy milk. Thus, it is expected that there will be an increase in applications of CLA for human 
health benefits.  
 
2.2 CLA and Body Composition Change 
 The human body is typically composed of fat, muscle (protein or lean body mass), water 
and bone, and measuring body composition is an efficient way to assess obesity. Most of the 
initial CLA studies in animals used this method to determine CLA’s anti-obesity effects. Since 
the first finding of the effect of CLA on body composition changes in mice in 1997,27 numerous 
studies have reported that CLA supplementation contributed to modulate body composition by 
reducing body fat and/or increasing lean body mass in various mammalian models.13-15,22,25 
Herein, the previous studies in mice and rats on the changes in body composition including both 
body fat mass and lean body mass are described in Tables 2.1 and 2.2. Among about 100 human 
studies on body fat regulation, Table 2.3 summarizes the clinical trials measured changes of both 
body fat reduction and lean body mass. 
  
2.2.1 Effects of CLA on Body Fat Reduction 
 One of the most attractive aspects of CLA is to reduce body fat mass through various 
mechanisms.15,16 According to the experimental purpose, previous studies have adopted different 
strains, genders, forms and concentrations of CLA and varying durations in mouse studies (Table 
2.1). The effect of CLA on body fat reduction is likely to be the most responsive in mice, where 
previous studies at levels of 0.5-2.2% of dietary CLA mixture or 0.2% of single isomer have 
shown a decrease in body fat mass by 40-80%.22 In the same context, 0.5-3.0% CLA-fed rats 
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Table 2.1. Effects of conjugated linoleic acid (CLA) on body composition in mice 
References 
Mouse 
 
CLA Supplementation  Resultse  Muscle Metabolism 
Straina Genderb Formc Dosage (%)d Duration   BW BFM LBM 
Food 
Intake 
Energy 
Expendituref Biomarkers
g
 
Park et al., 199727 ICR F+M Mixture 0.5 4 weeks  - ↓ ↑ ↓  ↑ CPT 
West et al., 199828 AKR/J M Mixture 1.0-1.2 6 weeks  ↓ ↓ - ↓ ↑ EE / ↓ RQ  
DeLany et al.,  
199929 
AKR/J M Mixture 0.25-1.0 6 weeks  ↓ ↓ ↑ -   
Park et al., 199930 ICR F Mixture 0.5 8 weeks - ↓ ↑ ↓   
Park et al., 199931 ICR F Mixture / 
c9t11/t10c12 
0.5 4 weeks ↓ by 
t10c12 
↓ ↑ ↓   
West et al., 200032 AKR/J M Mixture 1.0 5 weeks - ↓  - ↑ EE  
Tsuboyama et al., 
200033 
C57BL/6J F Mixture 1.0 5 months - ↓ -   ↓ TNF-α /  
↑ GLUT4 
Park et al., 200134 ICR M Mixture 0.1 4 weeks - ↓ ↑    
Ohnuki et al., 200135 ddY M Mixture 0.25-1.0 4 and 8 
weeks 
 ↓ ↓ -  ↑ Oxygen 
consumption 
 
Peters et al., 200136 PPARα-
KO 
M Mixture 0.5 4 weeks  ↓ ↓ ↑   ↑ CPT1 / ↑ UCP2 
Park et al., 200137 ICR F Mixture 0.3 2 weeks  ↓ - - ↓   
Ntambi et al., 200238 ICR F Mixture 1.0 4 weeks - ↓ ↑    
Hayman et al., 200239 BALB/c M Mixture 0.1-2.0 4 weeks  ↓ ↓ ↑  ↔EE/↔VA/↔RER 
↔ Oxygen 
consumption 
 
Warren et al., 200340 C57BL/6N F c9t11/t10c12 0.5 8 weeks  ↓ ↓ -    
Chardigny et al., 
200341 
ICR F+M c9t11/t10c12 1.0 6 weeks - ↓ ↑    
(Continued) 
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Table 2.1. Continued 
References 
Mouse 
 
CLA Supplementation  Resultse  Muscle Metabolism 
Straina Genderb Formc Dosage (%)d Duration   BW BFM LBM 
Food 
Intake 
Energy 
Expendituref Biomarkers
g
 
Terpstra et al., 200342 BALB/c M Mixture 0.5 6 weeks  ↓ ↓ ↑ - ↑ EE  
Hargrave et al., 
200443 
MH/ML M Mixture 0.5 8 weeks  ↓ ↓ - ↓   
Park et al., 200444 ICR M t10c12 0.5 3 weeks - ↓ ↑    
Javadi et al., 200445 BALB/c M Mixture 0.5 3 and 12 
weeks 
 ↓ ↓ ↑    
Ohashi et al., 200446 C57BL, 
KK, KKAy 
F Mixture 0.5 4 weeks  ↓ ↓ - -   
Javadi et al., 200447 BALB/c M Mixture 4.0 5 weeks - ↓ - - ↑ EE  
Park et al., 200548 ICR F Mixture 0.5 4 weeks - ↓ ↑ ↓   
de Roos et al., 200549 ApoE KO M c9t11/t10c12 2.1 12 weeks  ↓ ↓ - -   
Hargrave et al., 
200550 
 M Mixture 0.5 2 and 8 
weeks 
 ↓ ↓ - ↓   
Winzell et al., 200651 C57BL/6J F Mixture 1.0 12 weeks  ↓ ↓ ↑ -   
Bhattacharya et al., 
200652 
BALB/c M Mixture 0.5 14 weeks  ↓ ↓ -  ↑ EE   
Viswanadha et al., 
200653 
CD-1 F t10c12 0.15/0.3 6 weeks - ↓ -    
Park et al., 200754 ICR F+M Mixture 0.5 4 weeks  ↓ ↓ ↑ ↓   
Rahman et al., 200755 C57BL/6J F Mixture 0.5 8 weeks  ↓ ↓ - -   
Javadi et al., 200756 BALB/c M Mixture 0.5 4 weeks  ↓ ↓ - - ↑ EE   
(Continued) 
7 
Table 2.1. Continued 
References 
Mouse 
 
CLA Supplementation  Resultse  Muscle Metabolism 
Straina Genderb Formc Dosage (%)d Duration   BW BFM LBM 
Food 
Intake 
Energy 
Expendituref Biomarkers
g
 
Park et al., 200715 ICR M Mixture 0.5 4 weeks  ↓ ↑    
Hur et al., 200957 N2KO F     t10c12 0.5 12 weeks  ↓ ↓ -    
Rahman et al., 200958 C57BL/6J F Mixture / 
c9t11/t10c12 
0.5 6 months   ↑   ↓ TNF-α / ↓ IL-6 
Andreoli et al., 200959 CF-1 M Mixture 0.3 4 weeks - ↓ -    
Halade et al., 200960 C57BL/6J F Mixture / 
c9t11/t10c12 
0.5 6 months  ↓ ↓ ↑ -   
Moon et al., 200961 ob/ob M Mixture 1.0 6 weeks  ↓ ↓ ↑ -   
Halade et al., 201062 C57BL/6J F Mixture / 
c9t11/t10c12 
0.5 6 months  ↓ ↓ ↑ -   
Park et al., 201063 129Sv/J F Mixture 0.5 4 weeks  ↓ ↓ ↑ ↓ ↑ EE / ↓ RQ ↑ CPT-1 / ↑ UCP2  
/ ↑ GLUT 4 
Parra et al., 201064 C57BL/6J M Mixture 3/10 
mg/day 
5 weeks  ↓ ↓ - -   
Halade et al., 201165 C57BL/6J F Mixture / 
c9t11/t10c12 
0.5 6 months  ↓ ↓ ↑    
Park et al., 201166 ICR M Mixture / 
c9t11/t10c12 
0.22/0.5 4 weeks - ↓ ↑ -   
Fedor et al., 201367 C57BL/6N F      t10c12 0.5 4 weeks  ↓ ↓ -    
Scalerandi et al., 
201468 
CF-1 M Mixture 1.0 4 weeks  ↓ ↓ - -   
aApoE KO, apolipoprotein E knockout; ddY, Deutschland, Denken, and Yoken; MH, metabolic rate high; ML, metabolic rate low; N2KO, Nescient helix-loop-helix 2 gene 
knockout; PPARα-KO, peroxisome proliferator-activated receptor α knockout; SENCAR, sensitive to carcinogenesis. 
bF, female; M, male. 
cMixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer. 
dDosage (%) means a designated weight percentage of CLA in diet. 
eBW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease. 
fEE, energy expenditure; RER, respiratory energy ratio; RQ, respiratory quotient; VA, voluntary activity. 
gCPT, carnitine palmitoyltransferase ; GLUT4, glucose transporter type 4; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha; UCP2, uncoupling protein 2; ↔, no change. 
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Table 2.2. Effects of conjugated linoleic acid (CLA) on body composition in rats 
References 
Rat 
 
CLA Supplementation  Resultsd  Muscle Metabolism 
Strain Gendera Formb Dosage (%)c Duration   BW BFM LBM 
Food 
Intake 
Energy 
Expenditure Biomarkers
e
 
Stangl et al., 200069 SD M Mixture 3.0 7 weeks  ↓ ↓ ↑    
Azain et al., 200070 SD F Mixture 0.25/0.5 1, 5 and 7 
weeks 
- ↓ - -   
Sisk et al., 200171 Zucker M Mixture 0.5 5 and 8 
weeks 
 - - -    
Kim et al., 200272 SD M Mixture 0.5-1.0 9 weeks  - - -    
Yamasaki et al., 200373 SD M Mixture 1.5 3 weeks  - ↓ -    
Henriksen et al., 200374 Zucker F Mixture / 
c9t11/t10c12 
0.42 
g/day 
3 weeks ↓ by 
Mixture & 
t10c12 
↓ by 
t10c12 
-   ↓ protein carbonyl /  
↓ intramuscular TG / 
↑ glucose uptake 
by Mixture & t10c12  
Sanders et al., 200475 Zucker F Mixture / 
c9t11/t10c12 
0.42 
g/day 
3 weeks ↓ by 
Mixture & 
t10c12 
- -    
Botelho et al., 200876 Wistar M Mixture 2.0 6 weeks - ↓ ↑ ↑   
Ogborn et al., 200877 Han: 
SPRD-cy 
F+M Mixture 1.0/2.0 12 weeks - ↓ -    
Roy et al., 200878 SD M Mixture 1.0 8 weeks  - - -    
DeGuire et al., 201379 SD F+M Mixture 1.0 16 weeks  - - -    
de Almeida et al., 
201580 
Wistar M Mixture 1.5 9 weeks  - - -    
aF, female; M, male. 
bMixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer. 
cDosage (%) means a designated a designated weight percentage of CLA in diet. 
dBW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease. 
eTG, triglyceride.
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Table 2.3. Effects of conjugated linoleic acid (CLA) on body composition in humans 
References 
Subject 
 
CLA Supplementation  Resultsc   
Characteristic Gendera Formb Dose (g/day) Duration   BW BFM LBM 
Energy 
Expenditured Other comments 
Berven et al., 
200081 
 Overweight / 
Obese 
F+M Mixture 3.4 12 weeks  ↓ - -   
Blankson et al.,  
200082 
Overweight / 
Obese 
F+M Mixture 1.7/3.5/
5.1/6.8 
6 and 12 
weeks 
 - ↓ 1.7, 3.4 and 
6.8 at 12 wk 
↑ 6.8 at 
12 wk 
  
Zambell et al.,  
200083 
Normal F Mixture 2.5 9 weeks  - - - ↔ RMR /↔ REM   
Kreider et al.,  
200284 
 Normal / 
Overweight 
M Mixture 6.0 4 weeks  - - -   
Riserus et al.,  
200285 
Obese M Mixture /  
t10c12 
3.4 12 weeks ↓ by t10c12 ↓ by Mixture 
and t10c12 
-  Subjects with 
metabolic 
syndrome 
Kamphuis et al.,  
200386 
Overweight F+M Mixture 1.8/3.6 13 weeks - ↓ ↑ ↑ RMR Weight regain 
Gaullier et al., 
200487 
Overweight F+M Mixture 
(TG/Free  
form) 
3.6/3.4 1 year ↓ ↓ ↑ ↑ EE Free form 
increased LBM / 
↓ food intake 
Malpuech-
Burugere et al., 
200488 
Overweight F+M TG of c9t11 
and t10c12 
1.5/3.0 18 weeks - - -  ↓ Food intake 
Riserus et al., 
200489 
Obese M TG of c9t11 3.0 12 weeks  ↑ - -   
Gaullier et al., 
200590 
Overweight F+M Mixture 
(TG/Free  
form) 
3.6/3.4 2 year  ↓  ↓ -  1 year extension 
open study /  
↓ food intake 
Colakoglu et al., 
200691 
Normal F Mixture 3.6 6 weeks  ↓  ↓ ↑   
Larsen et al., 
200692 
 Overweight / 
Obese 
F+M Mixture 3.4 1 year  - - -  Weight regain / 
hypocaloric diet 
(Continued) 
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Table 2.3. Continued 
References 
Subject 
 
CLA Supplementation  Resultsc   
Characteristic Gendera Formb Dose (g/day) Duration   BW BFM LBM Energy Expenditured Other comments 
Pinkoski et al., 
200693 
Unknown F+M Mixture 5.0 7 weeks    ↓ ↑ ↔ RMR ↓ Protein 
degradation 
Gaullier et al., 
200794 
 Overweight / 
Obese 
F+M Mixture 3.4 6 months  -  ↓ ↑  ↔ Calorie intake 
Lambert et al., 
200795 
 Normal / 
Overweight 
F+M Mixture 2.6 12 weeks  - - - ↔ RMR ↔ Appetite 
Laso et al., 200796  Overweight / 
Obese 
F+M Mixture 3.0 12 weeks  - ↓ -   
Nazare et al.,  
200797 
Normal / 
Overweight 
F+M Mixture  
(TG) 
2.8 14 weeks  - - - ↑ RMR ↓ Food intake 
Steck et al.,  
200798 
Obese F+M Mixture 3.2/6.4 12 weeks  - - ↑ ↔ RMR /↔ RQ  
Tarnopolsky et  
al., 200799 
Normal / 
Overweight 
F+M Mixture 5.4 + 5 g 
creatine 
monohydrate 
6 months  - ↓ ↑  Cosupplementation/
aging study model 
Watras et al.,  
2007100 
Overweight F+M Mixture 3.2 6 months  ↓ ↓ - ↑ RMR ↔ Energy intake 
Diaz et al., 
2008101 
 Overweight / 
Obese 
F Mixture 1.8 + 0.4 mg 
creatine 
picolinate 
12 weeks  - - -  Cosupplementation/
Premenopausal 
Park et al., 
2008102 
 Overweight / 
Obese 
F+M Mixture 2.4 8 weeks  ↓ - -  ↓ Food intake 
Sneddon et al., 
2008103 
 Normal / 
Obese 
M Mixture 2.3 + 1.3 g  
ω-3 fatty acid 
12 weeks  ↑ - ↑  Cosupplementation/
Crossover design 
Norris et al., 
2009104 
Obese F Mixture 6.4 16 weeks  ↓ ↓ -  Type 2 diabetes / 
postmenopausal 
Raff et al., 
2009105 
 Normal /  
Overweight / 
Obese 
F Mixture / 
c9t11 
5.5/4.7 16 weeks  - ↓ by 
Mixture 
↑ by 
Mixture 
 Postmenopausal 
(Continued) 
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Table 2.3. Continued 
References 
Subject 
 
CLA Supplementation  Resultsc   
Characteristic Gendera Formb Dose (g/day) Duration   BW BFM LBM Energy Expenditured Other comments 
Cornish et al., 
2009106 
Obese F+M Mixture 4.3 + 9 g 
creatine 
monohydrate 
+ 36 g whey 
protein 
5 weeks  - - ↑  ↔ Energy intake 
Racine et al., 
2010107 
Overweight / 
Obese 
F+M Mixture  
(TG) 
2.4 7 months  ↓ ↓ ↑  Childhood model 
Joseph et al.,  
2011108 
Overweight / 
Obese 
M Mixture / 
c9t11 
2.8/2.7 8 weeks  - - -  Crossover design 
Chen et al.,  
2012109 
Overweight / 
Obese 
F+M Mixture 1.7 12 weeks  ↓ ↓ -   
Macaluso et al., 
2012110 
 Normal / 
Overweight 
M Mixture 4.8 3 weeks  - - -  Crossover design / 
serum testosterone ↑ 
Lopez-Plaza et al., 
2013111 
Overweight F+M Mixture 3.0 24 weeks  ↓ ↓ -   
Shadman et al., 
2013112 
Overweight F+M Mixture 2.4 + 100 
IU/day 
Vitamine E 
8 weeks  - - -  Cosupplementation/
Type 2 diabetes 
Ormsbee et al., 
2014113 
Overweight / 
Obese 
F+M Mixture CLA +  
Green tea + 
BCAA 
(branched 
chain amino 
acid) 
8 weeks  ↓ - -  Cosupplementation 
aF, female; M, male. 
bMixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer; TG, triglyceride form; Free form, free 
fatty acid form. 
cBW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease. 
dEE, energy expenditure; RER, respiratory energy ratio; RMR, resting metabolic rate; RQ, respiratory quotient; ↔, no change. 
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accumulated less body fat, although the magnitude of the reduced body fat was dependent on the 
strain of rats and the site of the adipose tissue (Table 2.2). Specifically, CLA supplementation in 
Sprague-Dawley rats showed the reduced peritoneal and parametrial fat mass by 25-30%.70 
Additionally, 0.5% CLA diets in OLETF rats induced 14% and 44% less fat accumulation in 
omental and epididymal adipose tissues, respectively.114 Along with the availability of purified or 
enriched CLA isomer, further studies have demonstrated the specific CLA isomers’ effects on 
body fat accretion. With respect to body fat reduction, the trans-10,cis-12 CLA isomer was 
identified as the primary active form in mice, not the cis-9,trans-11 isomer.18,31,58,62,115 In 
congruence with the mice study, the trans-10,cis-12 CLA isomer remarkably induced a reduction 
of body weight and fat mass in OLETF rats.116 Also, 1.5% CLA mixture fed Zucker diabetic fatty 
(ZDF) rats had significantly lower body weight gain and fat mass, while it was observed that the 
cis-9,trans-11-fed group had no effect on changes in body composition, especially body fat 
reduction.117 In another isomer-specific study, the eight week feeding trans-10,cis-12 isomer did 
not achieve significant changes in body weight and adipose mass in the same rat strain.118  
 On the basis of evident results from animal studies, a number of clinical trials have been 
carried out to determine the effects of CLA on body fat accretion.14,22,119 Human intervention 
studies of supplemented CLA mostly used the CLA mixture form (cis-9,trans-11 and trans-
10,cis-12 isomers). Although accumulating evidence elicits the effect of CLA on the reduction of 
body fat mass in humans,120 it is less responsive to animal studies, especially compared to the 
mouse model.  
In addition, the subjects’ weight status may contribute to CLA’s efficacy on body fat 
control. Normal weight subjects supplemented with 0.7-5.5 g of CLA mixture for 4-16 weeks had 
a decreased body fat mass by 4-20%,91,93,105,121-123 whereas overweight and obese individuals 
treated with 1.7-6.8 g of CLA mixture for 4-104 weeks showed reductions of 3-
15%.81,85,88,89,98,108,124-127 However, other studies observed no effect of CLA on body fat mass in 
both subject groups (normal and overweight/obese).22 Interestingly, the study in 6-10 year old 
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overweight and obese children at levels of 3 g of CLA mixture for 7 months significantly reduced 
peripheral and abdominal body fat accumulation (%).107 Moreover, Ha et al.128 reported that 15-
year-old obese volunteers supplemented with 6 g of CLA mixture for 6 months had decreased 
body weight and fat content, as well as improved physical activity. To date, there are two meta-
analyses focused on both body weight and body fat mass to establish a significant dose and 
duration for CLA’s efficacy.129,130 Whigham et al.129 reported that 3.2 g/day CLA supplementation 
led to significantly reduce body fat mass in humans, although it was a modest loss. A study by 
Blankson et al.82 supported this finding, demonstrating that CLA’s effective dose of body fat 
reduction plateaued at 3.4 g/day between the range of 1.7 and 6.8 g/day. Along with CLA’s dose 
efficacy, they reported that supplementation with CLA up to 6 months linearly reduced body fat, 
then attenuated response and eventually showed no additional effect at approximately 2 years. 
This is consistent with a meta-analysis in overweight and obese individuals based on fifteen 
previous clinical trials,130 indicating long-term CLA intake significantly induces loss in body 
weight and fat mass. 
Combining all these results together, CLA likely reduces body fat mass. However, it is 
not mirrored in body weight decrease, since CLA might be involved in other composition 
changes in the body. In fact, the previous clinical studies showed no changes in body weight by 
CLA supplementation even though body fat reduction occurred.82,86,94,96,99,105,113 In support of 
these observations, body fat mass and lean body mass were simultaneously influenced by CLA 
supplementation. Particularly, seven human intervention studies 82,87,91,93,94,99,105 along with eight 
publications in rodents27,29-31,54,62,63,69 demonstrated reduced body fat accretion as well as increased 
lean body mass by CLA supplementation. Thus, it is important to further investigate the effects of 
CLA on lean body mass. 
  
2.2.2 Effects of CLA on Increased Lean Body Mass 
 In terms of the effects of CLA on body composition change, most studies have been 
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focused on the decreased body fat mass. However, a growing body of evidence elucidates the 
importance of increased lean body mass, body proteins (%), or specific skeletal muscle tissue 
(gastrocnemius and quadriceps muscle) weights on anti-obesity effects of CLA, as lean body 
mass is highly associated with energy expenditure.14-16,120  
To elicit CLA’s effects on the change of lean body mass, various studies either including 
or excluding exercise regimens in animals and humans were conducted (Table 2.1, 2.2 and 2.3). 
Along with reduced body fat mass, 0.25-0.5% CLA mixture supplementation significantly 
increased body protein (%) in body composition in mice.27,29,30,54,63,131,132 The trans-10,cis-12 CLA 
isomer significantly increased protein accretion in various mouse models.18,31,58,62 These results 
suggest that the trans-10,cis-12 CLA isomer plays a critical role in body composition changes, 
since in most CLA supplementation studies on body fat reduction as well as increased lean body 
mass, the effect of the cis-9,trans-11 CLA isomer was not observed. Interestingly, in over 12-
month-old C57BL/6J, 0.5% of the trans-10,cis-12 isomers and CLA mixture for a 6 month 
intervention showed prevention of age-associated skeletal muscle loss without a training 
regimen.58,60 In Sprague-Dawley rats, 3.0% CLA mixture supplementation increased lean body 
mass.69 This change was also shown with 0.5-1.0% CLA treatment in Wistar rats for 6-10 
weeks.133,134 It was suggested that CLA supplementation caused repartitioning of body 
composition, less adipose depots and more lean mass.69 There are consistent reports that CLA 
contributes to increased lean mass in different cross-bred pigs. The CLA mixture between 0.25 
and 2% acted as a repartitioning agent to induce decreased back fat and increased lean body mass 
in pigs.135-139  
The intervention study of CLA in humans yielded less substantial and partially contrary 
results compared to those observed in the animal models (Table 2.3). In fact, the results in human 
studies varied with regard to the changes in body weight, body fat mass and lean body mass 
(Table 2.4). In terms of the prevention of obesity, group I and II in Table 2.4 are the ideal 
outcomes after CLA supplementation. While increased lean body mass may group a perceived 
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body weight gain like group II and/or III, this change in body composition would also provide 
additional health benefits beyond simply a decreased value in body weight.  
Among clinical trials with CLA supplementation independent of exercise training, five 
of them reported that the body composition change of not only reduced body fat but also of 
increased lean body mass.86,87,94,105,107 Specifically, the duration of supplementation with CLA in 
these studies were 3-12 months, indicating the long-term intervention might be more helpful to 
increase lean body mass even without exercise. Moreover, two studies with no exercise regimen 
reported that supplemented CLA showed no body fat reduction but showed an increase of lean 
body mass.98,103 Schoeller et al.140 demonstrated the overall effects of CLA on lean body mass 
using a meta-analysis in 18 independent clinical studies. These studies made the conclusion that 
CLA supplementation led to a relatively rapid onset of increased lean body mass, however the 
total increase was not drastic (less than 1%). This result supports the previous mouse study,30 
implying CLA affects body composition through modulating lean muscle mass, prior to reducing 
fat mass. It suggests that CLA may target muscle metabolism to reduce body fat through 
metabolic alteration in skeletal muscle. 
 
Table 2.4. The grouping dependent on the changes in body weight (BW), body fat mass (BFM) 
and lean body mass (LBM) after CLA supplementation in human studies 
Group BW BFM LBM References 
I ↓ ↓ ↑ 87,91,107 
II - ↓ ↑ 82,86,93,94,99,105 
III ↑ - ↑ 103 
IV ↓ ↓ - 85,90,100,104,109,111 
V - - - 83,84,88,92,95,97,101,108,110,112,141 
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2.2.3 Mechanism of Body Composition Change by CLA 
 The source of energy intake is simply from consumed food, while source of energy 
expenditure comes from several forms such as basal metabolic rate (BMR), adaptive 
thermogenesis and physical activity. The regulation of body composition is relevant to energy 
balance, since energy intake over energy expenditure leads to the storage of excess energy as fat 
in the body. Multiple mechanisms to better understand the CLA effects on body composition 
change have been demonstrated.15,16,142 These approaches are mostly associated with CLA-
mediated energy modulation including lowered energy intake and enhanced energy expenditure 
along with the inhibition of fat accumulation in adipose tissue.  
 
2.2.3.1 Regulation of Energy Balance by CLA 
 On the basis of previous observations demonstrating energy balance changes by CLA 
supplementation in animals and humans, the putative mechanisms of CLA on the regulation of 
energy balance are the reduction of food intake and the increase of energy expenditure.  
Early studies demonstrated CLA-fed mice showed a reduced food intake as a function of 
body fat reduction, whereas others have reported inconsistent results in comparison with the 
former (Table 2.1). Similarly, this discrepancy on food intake was reported in rat studies. In fact, 
two studies of CLA supplementation independent to exercise regimens reported decreased food 
intake in rats,117,143 while others observed no change in food intake by CLA.133,144-146 In theory, 
reduced food intake causes fewer gains of body weight and body fat, which may affect overall 
body composition changes. Herein, it is questionable whether body fat reduction by CLA is 
derived from decreased food intake or other causes. With regard to this question, the subsequent 
study clearly answered that CLA’s effects on body composition change were independent of 
lowered food intake by using a pair feeding comparison.54 This conclusion supports human 
clinical trials, since they did not support the correlation between CLA supplementation and 
reduced food intake.87,88,90,94,100,106,147 Thus, it is unlikely that food intake reduction by CLA is a 
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main function of body composition change.  
 Next, we should consider energy expenditure, as enhanced energy expenditure is a 
primary function that influences body composition, including body fat reduction. CLA 
supplementation has provided various pieces of evidence to show enhanced energy expenditure 
with increased oxygen consumption in animal models.17,28,32,35,63,116,131,133,148,149 In clinical trials 
CLA supplementation increased BMR (same as resting metabolic rate, RMR),86,97,100,150 whereas 
other studies did not report an influence of CLA on BMR regardless of changes to body 
composition.83,93,95,98 Thus, further human studies are needed to provide a more clear 
interpretation of the effect of CLA on basal metabolic rate.  
 CLA supplementation is likely involved in the activation of thermogenesis, as early 
studies demonstrated CLA upregulates uncoupling proteins (UCPs) expressed in various tissues 
such as adipose, liver and skeletal muscle in mice and rats.17,33,63,117,144,151,152 Adaptive 
thermogenesis is responsible in mitochondria-mediated biochemical processes, especially in 
combusting stored or excess energy into heat, where UCPs play a crucial role. UCP1 to UCP5 are 
expressed in distinct tissues in body, although their basic role to generate heat by using ATP is 
almost same.153  
 Along with the internal heat produced by BMR and thermogenesis, physical activity by 
contractile skeletal muscle works to expend energy, thus contributing to body fat reduction. 
Although the magnitude of energy expended in physical activity varies depending on the type 
(resistance or endurance training), intensity, duration and frequency of exercise, CLA 
supplementation may affect physical activity and subsequently regulate energy expenditure. In 
fact, previous studies in rodents reported that a combination of CLA supplementation with 
endurance training enhanced energy consumption,131,133,149 while the results of clinical studies 
were inconsistent.93,97,154 
 At the cellular level, energy expenditure may be explained by biochemical events. To 
convert stored or excess fat in the body into energy, fatty acid β-oxidation plays a pivotal role, 
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resulting in reduced body fat mass and subsequently leads to even or negative energy balance. 
Although increased fat oxidation in the CLA-fed animals might be estimated by the alteration of 
energy sources based on measurements of the respiratory quotient (RQ, the representative marker 
for assessment of a primary energy source either carbohydrate or fat),28,35,116,131,133,148,149 the 
upregulation of carnitine palitoyltransferase 1(CPT-1) in skeletal muscle as the direct marker for 
fatty acid β-oxidation provided more reliable evidence of enhanced lipid 
metabolism.17,18,27,36,63,145,155-158 Intriguingly, Close et al.150 reported supplemented groups with 4 g 
of CLA mixture for 6 months had significantly increased fat oxidation and energy expenditure 
during sleep in human subjects. 
 Herein, we discussed the effects of CLA on the regulation of energy balance by food 
intake and energy expenditure, suggesting CLA might lead to the negative energy balance 
(energy intake less than consumption) in the whole body. Thus, we need to look into the tissue-
specific functions of CLA.  
 
2.2.3.2 Effect of CLA on Adipocyte Metabolism 
  Adipose tissue undergoes two physiological and morphological events to grow: 
hyperplasia (increase in cell number) and hypertrophy (increase in cell size). While hyperplasia 
plays a critical role in proliferation of preadipocytes involved in adipogenesis, hypertrophy is 
responsible for the continuous storage of excess energy in adipose tissue, directly leading to 
adiposity.159 The mechanisms of CLA on adipocytes are elucidated to in in vitro and in vivo 
experimental models.15,16,119 The suggested mechanisms to date are (1) suppression of lipogenesis; 
(2) stimulation of lipolysis; (3) inhibition of adipogenesis; and (4) modulation of cytokines / 
adipokines. The trans-10, cis-12 CLA isomer, not the cis-9, trans-11 CLA isomer, is the active 
form in these mechanisms. Of particular importance, CLA mostly interacts with peroxisome 
proliferator-activated receptor γ (PPARγ), which is a key regulator of lipogenesis, lipolysis, 
adipogenesis and inflammation in adipocyte metabolism.160,161 
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 First, the putative mechanism to reduce body fat by CLA is the suppression of 
lipogenesis, since several studies reported that CLA supplementation attenuated the expression 
levels of stearoyl-CoA desaturase (SCD), acetyl-CoA carboxylase (ACC), fatty acid synthase 
(FAS) and sterol regulatory element-binding protein-1 (SREBP1).33,162-165 Second, CLA 
stimulates lipolysis via the activation of hormone sensitive lipase (HSL), inducing the 
mobilization of stored triglyceride and the subsequent release of free fatty acid and glycerol 
cleavage.161 However, there is still a debate regarding the effects of CLA on lipolysis.166-16827,31,167-
169
 Third, CLA inhibits adipogenesis through reduced PPARγ expression levels. The key 
transcription factors to induce adipogenesis are PPARγ and CAAT/enhancer binding proteins 
(C/EBPs). For differentiation from preadipocytes to adipocytes, C/EBPβ and C/EBPδ are 
primarily increased, activating the transcription of C/EBPα and PPARγ. Particularly, the trans-
10,cis-12 CLA isomer suppressed the activity of PPARγ and C/EBPs as well as related target 
genes such as acyl-CoA binding protein (ACBP) and perilipin on adipogenesis.163,164,170-173163,170,174 
Last, CLA may modulate cytokines such as nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) through IκB and IκB kinase (IKK), subsequently inducing an increase 
of tumor necrosis factor α (TNFα), interleukin (IL) 6 and 8 and IL-1β, associated with 
inflammatory mechanisms. In addition, CLA may induce adipokines like leptine and adiponectin, 
representing the total amount of adipose tissue, resulting in a decrease of TG synthesis and an 
increase of lipolysis.171-173,175,176 
Collectively, CLA may have the potential to regulate body composition change, 
although the magnitude of efficiency is dependent upon several variables. While the effects of 
CLA on adipocyte metabolism are supported by strong evidence, the role of CLA on skeletal 
muscle metabolism and its main organization of energy expenditure is not fully known. However, 
the previous studies showed that increased lean body mass and enhanced thermogenesis and fatty 
acid β-oxidation in muscle with CLA might be associated with skeletal muscle metabolism. 
Particularly, the interaction of CLA with exercise might be able to provide critical evidence of 
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CLA’s effects on metabolism in skeletal muscle. 
 
2.3 CLA and Skeletal Muscle Metabolism 
The potential effects of CLA on skeletal muscle metabolism have drawn relatively less 
interest, even though CLA also plays a central role in the regulation of energy balance in the 
body. Skeletal muscle typically accounts for nearly 40 % of the total body mass and acts as a 
significant regulator in overall energy metabolism.177 Generally, muscle metabolism is a term 
used to describe the complex biochemical reactions associated with the function and development 
in muscle. These reactions modulate energy metabolism in muscle, thereby influencing energy 
expenditure by the alteration of exercise ability and adaptive thermogenesis. The discovery of 
increased lean body mass and upregulated molecular markers predominately expressed in skeletal 
muscle, such as CPT1 and UCP2 and 3, by CLA supplementation in the previous studies provide 
the opportunity to uncover the correlation between CLA intake and muscle metabolism. 
 
2.3.1 Energy Metabolism in Skeletal Muscle 
 In general, energy is derived from glucose and fatty acids in skeletal muscle. In the 
muscle fibers, glucose and fatty acids are stored as modified structures, glycogen and 
triglycerides, respectively. Although energy substrates used by muscle depend on the type, 
intensity and duration of muscle work of the subject, skeletal muscle predominantly prefers to use 
energy sources from fatty acids at rest. On the other hand, during high-intensity performance, 
anaerobic metabolic pathways such as anaerobic glycolysis and the creatine kinase reaction 
provide energy as primary sources when aerobic metabolism alone is not possible to cope with 
energy demands in exercising muscle fibers.7-9 Low-intensity endurance exercise corresponding 
to less than 60% of maximal oxygen uptake, like jogging and swimming, consumes glucose and 
fatty acids as the primary energy sources during the first hour. Subsequently, prolonged 
endurance exercise during the following one to four hours causes the substantial uptake of free 
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fatty acids from intramuscular fat and stored triglycerides in adipose tissue as an energy source in 
skeletal muscle.178 Thus, prolonged endurance exercise is the better way to use up stored fat in the 
body through enhanced aerobic metabolism. 
Skeletal muscle integrates a number of biochemical processes for energy homeostasis 
between demand and supply. Cells in skeletal muscle store chemical energy as adenosine 
triphosphate (ATP) and phosphocreatine, which are immediate sources of energy. In terms of 
energy metabolism, skeletal muscle continuously produces energy derived from the hydrolysis of 
ATP in response to energy demand by skeletal muscle contraction and relaxation. During skeletal 
muscle work, ATPases break down ATPs and release 7.3 kcal per ATP of energy. This process is 
divided into anaerobic (absence of oxygen) and aerobic (presence of oxygen) metabolic 
pathways.178  
Glycolysis is the catabolic pathway for glucose in the cytosol under both anaerobic and 
aerobic conditions. In skeletal muscle, anaerobic glycolysis (breakdown of glycogen) permits 
energy supply under certain circumstances like high-intensity muscular performance when 
aerobic metabolism alone cannot provide sufficient levels of ATP. However, its net yield is only 
2 ATP by the oxidation of 1 mole of glucose. In addition to anaerobic glycolysis, the degradation 
of phosphocreatine by creatine kinase is another metabolic pathway that generates ATP under 
anaerobic conditions in skeletal muscle. 
Aerobic metabolism, especially aerobic glycolysis, in skeletal muscle takes place in the 
mitochondria, which is an efficient way to produce ATP through mitochondrial oxidative 
phosphorylation. Subsequently, a total of 38 ATP are produced from 1 mole of glucose under 
aerobic conditions. Along with oxidative phosphorylation in mitochondria, the citric acid cycle 
(Krebs or tricarboxylic acid (TCA) cycle) plays a critical role in energy generation in aerobic 
metabolism. In fact, the process of ATP production is tightly regulated among cytosolic 
glycolysis, mitochondrial β-oxidation and the citric acid cycle in skeletal muscle.179 
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2.3.2 Intracellular Signaling Pathways Regulating Muscle Metabolism  
 Skeletal muscle is a tissue to show metabolic plasticity in response to alterations of 
external and internal conditions such as nutrient deprivation during fasting or calorie restriction 
and contractile activity including exercise.180 Upon a decrease of nutrient availability, muscle 
switches its mode from glucose to fatty acid utilization as a main energy substrate.181 In response 
to endurance exercise, skeletal muscle triggers a remodeling fiber-type from oxidative slow-
twitch to glycolytic fast-twitch fibers.11 These adaptations in skeletal muscle are accompanied by 
an increase in mitochondrial biogenesis, which are phenotypic alterations: increased volume 
(content per gram of tissue) and changed composition (protein-to-lipid ratio in inner 
mitochondrial membrane) in mitochondria.10 Moreover, metabolic reactions including aerobic 
glycolysis, fatty acid β-oxidation, TCA cycle and oxidative phosphorylation rely on 
mitochondria, as these metabolic events take place in mitochondria, suggesting that enhanced 
mitochondrial biogenesis contributes to increased energy expenditure.182 The purpose of these 
metabolic alterations is to enhance energy production. Consequently, in order to properly regulate 
energy homeostasis, these adaptations positively regulate various molecular biomarkers involved 
in energy metabolism in skeletal muscle.180 
 A number of regulators participate in these adaptive responses in skeletal muscle, among 
them AMP-activated protein kinase (AMPK) is the prime initial sensor of fuel and energy status 
in skeletal muscle.183 Particularly, AMPK controls a regulatory pathway in fatty acid β-oxidation. 
AMPK negatively activates acetyl-CoA carboxylase (ACC), inducing the inhibition of malonyl-
CoA, which is the suppressor of CPT1 (a rate-limiting enzyme for fatty acids β-oxidation in 
mitochondria). As a consequence of reduced susceptibility to this shuttling system, fatty acid β-
oxidation is increased. Similar to AMPK, sirtuin 1 (SIRT1, a conserved nicotinamide adenine 
dinucleotide (NAD)+-dependent deacetylase) acts as a sensor in response to the metabolic stimuli 
such as stress, starvation or calorie restriction. SIRT1 regulates several transcriptional factors 
such as protein 53 (p53), forkhead box O (FOXO) and NFκB. SIRT1 has drawn special attention 
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to the factor working for longevity.184 Indeed, AMPK and SIRT1 may coherently mediate the 
response at the cellular level to stress and the reduced nutrient availability in skeletal muscle.185 
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a downstream 
marker regulated by AMPK and SIRT1, is an inducible coactivator and a master regulator for 
mitochondrial biogenesis, which orchestrates several transcription factors such as PPARs, nuclear 
respiratory factor (NRF) 1 and 2, estrogen-related receptor α (ERRα) and myocyte enhancer 
factor 2 (MEF2), to initiate mitochondrial biogenesis and induce the change in fiber 
characteristics in skeletal muscle.186,187  
 Skeletal muscle is classified into three different fiber types in humans and four different 
fiber types in rodents that have different physiological and metabolic characteristics. Typically, 
skeletal muscle fibers are divided into two subcategories, slow-twitch and fast-twitch, and are 
correlated with contractile properties.188 The fiber in human is composed of three myosin heavy 
chain (MHC) isoforms: MHC I, MHC IIa, and MHC IIx/d. MHC I is slow twitch type I fibers, 
which has a greater mitochondrial content, oxidative capacity and resistance to fatigue by using 
fatty acids as a main energy source; compared to MHC IIx/d, a fast twitch type II fiber as known 
glycolytic fiber that uses glucose and phosphocreatine as a primary energy provider; the 
peculiarity of MHC IIa is intermediate between MHC I and IIx/d.189  
 The first genes to be implicated as a fiber type transformation are PGC-1α and PPARδ. 
In transgenic mice, ectopically expressing PGC-1α in skeletal muscle induces muscle fiber 
conversion of fast-twitch type II fibers into slow-twitch type I fibers.190 In a similar manner, the 
overexpression of PPARδ (the most abundant form of PPARs in skeletal muscle) interacts with 
PGC-1α and is highly involved in the development of mitochondrial oxidative type I fibers in 
skeletal muscle.191,192 Taken together, a signaling cascade from AMPK to PPARδ is a relevant 
metabolic pathway to regulate metabolism in skeletal muscle. Thus, we primarily target this 
pathway to decipher the mechanism of CLA on skeletal muscle metabolism. 
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2.3.3 Effects of CLA on Skeletal Muscle Metabolism 
 It has been revealed that long-chain fatty acids (LCFAs) with over 14 carbons, including 
CLA, are primary endogenous ligands of the nuclear receptor family of transcription factors 
PPARs (PPARα, γ and δ). Indeed, it is known that LCFAs regulate energy metabolism in skeletal 
muscle.193  
 With regard to the regulation of skeletal muscle metabolism, the previous studies 
reported the effects of CLA isomers and mixture on AMPK expression levels in murine skeletal 
muscle cells. Both the cis-9,trans-11 and trans-10,cis-12 isomers stimulated the phosphorylation 
of AMPK (active form), resulting in improved muscle energy metabolism.194-196 In addition, each 
CLA isomer positively regulates ACC expression levels, indicating CLA treatment may affect 
enhanced fatty acid β-oxidation.194,196 The cis-9,trans-11 CLA isomer showed elevated AMPK 
phosphorylation with lower concentrations (~50 µM), while the trans-10,cis-12 isomer gradually 
activated phosphorylated AMPK up to 120 µM in a dose-dependent manner, and then 
plateaued.195 Compared to several studies of CLA on AMPK, it is limited on the effect of CLA on 
SIRT1 activity in skeletal muscle, even though AMPK and SIRT1 both mutually regulate and 
share many common target molecules.185  
 Although sufficient evidence demonstrating the role of CLA in mitochondria in skeletal 
muscle has not yet been provided, recent studies reported direct and/or indirect effects of CLA on 
the biochemical alteration of several molecular markers associated with mitochondrial biogenesis 
and metabolism.18,58,152,197-199 In fact, CLA treatment in human skeletal muscle cells did not affect 
the activity of PGC-1α, a primary regulator in mitochondrial biogenesis, even when 
mitochondrial content was increased by CLA.197 In a similar context, CLA fed mice and rats 
demonstrated no significant differences in PGC-1α compared to controls.152,198 On the other hand, 
CLA supplementation significantly upregulated molecular biomarkers such as succinate 
dehydrogenase, cytochrome c oxidase, superoxide dismutase 2, catalase and glutathione 
peroxidase in skeletal muscle, resulting in increased ATP production and thermogenesis via 
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improved oxidative phosphorylation and anti-oxidative capacity in rodent models.58,152  
 In regards to the effect of CLA on PPARδ, one of key regulators in muscle fiber type 
transformation, 50 µM of CLA mixture added to murine muscle cells showed a significant 
increase in PPARδ expression levels.199 Supporting this result, Kim et al.18 reported the trans-
10,cis-12 CLA isomer supplementation significantly upregulated PPARδ gene expression level in 
mouse skeletal muscle, while Parra et al.198 observed no CLA effect on PPARδ and muscle fiber 
change in mice. Although further investigation is required in in vivo studies for a better 
understanding on the correlation between CLA supplementation and muscle fiber type switch, 
CLA fed pigs showed a remarkably altered gene expression of muscle fiber types.200,201 In these 
studies, 1.2-2.0% of CLA supplementation significantly increased the expression levels of 
oxidative type I fiber, but not the expression levels of glycolytic type IIb and IIx fibers in skeletal 
muscle. 
 
2.3.4 Effect of CLA on Physical Activity 
 On the basis of the effects of CLA on increased muscle mass relative to fat mass gains, a 
number of studies in animals and humans were carried out to evaluate the interaction of CLA 
supplementation with exercise (Table 2.5 and 2.6). Exercise is typically divided into two distinct 
trainings, resistance and endurance, relying on the metabolic system to produce ATP by 
anaerobic and aerobic conditions, respectively. The previous animal studies of supplemented 
CLA along with exercise provided a better understanding of improved endurance capacity via 
mitochondrial fatty acid β-oxidation than resistance capacity (Table 2.5). In fact, 0.5-1.0% CLA 
supplementation combined with endurance training showed a significantly greater fat oxidation in 
skeletal muscle, resulting in an increased maximum swimming or running capacity in mice.149,202-
204
 Specifically, Kim et al.18 reported that the trans-10,cis-12 isomer increased the maximum 
running time and distance significantly over the cis-9,trans-11 treated animals in the trained-
mice. Interestingly, the effect of CLA on physical activity is also supported by animal studies that 
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measured voluntary activity (non-exercise physical activity), showing increased voluntary 
movement along with the upregulation of CPT1 and UCP2.17,205 In rat models, no synergistic 
effects of CLA treatment and exercise training on endurance capacity and lean body mass were 
observed.133,134 
 Currently, there have been seventeen CLA intervention studies reported in humans 
associated with exercise (Table 2.6). Among them, ten studies have tested exercise outcomes. 
Overall, the outcomes in physical activity of CLA supplementation dependent on exercise were 
inconsistent. Five clinical trials demonstrated the positive results of combined CLA with a 
resistance-training regimen.82,93,99,106,110 Only Colakoglu et al.91 reported a synergistic effect of 
CLA with endurance training. Furthermore, there were four clinical trials that evaluated the effect 
of CLA supplementation without exercise on physical activity.94,100,128,206 Among them, two 
studies showed improved physical activity by CLA treatment for 3 or 6 months.100,128 
 Four studies in humans evaluated the effects of cosupplementation of CLA with other 
supplements such as creatine monohydrate, chromium picolinate, whey protein or amino acids 
under physical training.99,101,106,207 Two cosupplementation studies of CLA and creatine 
monohydrate for short- (5 weeks) or long-term (6 months) interventions, accompanied with 
resistance training, showed increased lean body mass and improved strength compared to the 
control.99,106 Interestingly, Macaluso et al.110 carried out a clinical trial to investigate the effect of 
CLA with resistance training on testosterone levels in serum. This study designed a short-term 
intervention (3 weeks), showing no change of body weight, fat mass and lean body mass. 
However, serum testosterone levels were significantly increased by CLA supplementation and 
resistance exercise. Subsequently, Barone et al.204 demonstrated that CLA supplementation 
promoted endurance capacity in mice trained on the rotarod via the upregulation of testosterone 
biosynthesis. Recently, Usui et al.208 suggested that enhanced mitochondrial biogenesis in skeletal 
muscle led to the testosterone-induced increase in energy expenditure. This may provide another 
clue to help explain how CLA can enhance energy expenditure and improve physical activity via 
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Table 2.5. Effects of conjugated linoleic acid (CLA) with exercise regimes on physical activity in animals 
References 
Animal 
 
CLA Supplementation  Resultsd   Muscle Metabolism  
Strain Gendera Formb Dosagec Duration   BW BFM LBM Exercise Type 
Energy 
Expendituree Biomarkers
f
 
Exercise 
Outcome 
Mizunoya et al., 
2005149 
BALB/c 
Mice 
M Mixture 0.5% 1 week - ↓ - Endurance 
(Swimming 
& Running) 
↓ RER 
↑ Fat oxidation 
↑ LPL ↑ 
Bhattacharya et al., 
2005131 
BALB/c 
Mice 
M Mixture 0.4% 14 weeks  ↓ ↓ ↑ Endurance 
(Running) 
↔ EE   
Di Felice et al., 
2007132 
ICR Mice M Mixture 0.425 
mg/day 
6 weeks  -  ↑ Endurance 
(Running) 
 ↑ Muscle 
hypertrophy 
 
Banu et al., 2008209 C57BL/6 
Mice 
F Mixture 0.5% 10 weeks  ↓ ↓ ↑ Endurance 
(Running) 
  
 
Zhang et al., 2009210 ICR Mice M Mixture 0.5% 18 weeks  ↓   Endurance 
(Swimming) 
  ↔ 
Kim et al., 2010202 BALB/c 
Mice 
M Mixture 1.0% 10 weeks  ↓   Endurance 
(Running) 
  ↑ 
Kim et al., 201218 129 Sv/J 
Mice 
M c9t11/ 
t10c12 
0.5% 6 weeks  ↓ ↓ ↑ Endurance 
(Running) 
 ↑ CPT1 / ↑ UCP2 
/ ↑ PPARδ 
↑ by 
t10c12 
Hur et al., 2013203 ICR Mice F Mixture 1.0% 6 weeks  ↓ ↓  Endurance 
(Running) 
  ↑ 
Barone et al., 2013204 BALB/c 
Mice 
M     Mixture 0.5% 6 weeks  ↓  ↑ Endurance 
(Running) 
 ↑ Testosterone ↑ 
Shen et al., 2015211 129 Sv/J 
Mice 
M t10c12 0.1% 7 weeks  ↓ ↓  Endurance 
(Running) 
   
             
Mirand et al., 2004212 Wistar 
Rats 
M Mixture / 
 c9t11/t10c12 
1.0% 6 weeks  - - - Endurance 
(Running) 
   
Faulconnier et al., 
2006213 
Wistar 
Rats 
M Mixture / 
 c9t11/t10c12 
1.0% 6 weeks  - ↓  Endurance 
(Running) 
   
Mirand et al., 2006133 Wistar 
Rats 
M Mixture / 
 c9t11/t10c12 
1.0% 6 weeks  -  ↑ by 
Mixture 
Endurance 
(Running) 
   
Salgado et al., 2012134 Wistar 
Rats 
F+M Mixture 0.5% 10 weeks  ↓ ↓ ↑ Endurance 
(Swimming) 
   
aF, female; M, male. 
bMixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer. 
cDosage (%) means a designated weight percentage of CLA in diet. 
dBW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease. 
eEE, energy expenditure; RER, respiratory energy ratio; ↔, no change. 
fCPT1, carnitine palmitoyltransferase 1; LPL, lipoprotein lipase; PPARδ, peroxisome proliferator activated receptor δ; UCP2, uncoupling protein 2. 
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Table 2.6. Effects of conjugated linoleic acid (CLA) with exercise regimes on physical activity in humans 
References 
Subject 
 
CLA Supplementation  Resultsd   Muscle Metabolism  
Characteristic Gendera Formb Dosagec Duration BW BFM LBM Exercise Type 
Energy 
Expendituree Biomarkers
f
 
Exercise 
Outcome 
Blankson et al.,  
200082 
 Overweight / 
Obese 
F+M Mixture 1.7/3.5/
5.1/6.8 
6 and 12 
weeks 
 - ↓ 1.7, 3.4 and 
6.8 at 12 wk 
↑ 6.8 at 
12 wk 
Standardized 
training 
  ↑ 
Thom et al., 
2001123 
Normal F+M Mixture 1.8 12 weeks  -  ↓  Strenuous    
Kreider et al.,  
200284 
 Normal / 
Overweight 
M Mixture 6.0 4 weeks  - - - Resistance   ↔ 
Loeffelholz et 
al., 2003 
Overweight F+M Mixture 3.8 6 months  -  ↓  Resistance    
Colakoglu et al., 
200691 
Normal F Mixture 3.6 6 weeks  ↓  ↓ ↑ Endurance   ↑ 
Pinkoski et al., 
200693 
Unknown F+M Mixture 5.0 7 weeks    ↓ ↑ Resistance ↔ RMR  ↑ 
Adams et al., 
2006214 
 Overweight / 
Obese 
M Mixture 3.2 4 weeks  -   Resistance    
Nazare et al.,  
200797 
 Normal / 
Overweight 
F+M Mixture  
(TG) 
2.8 14 weeks  - - - Regular 
training 
↑ RMR    
Tarnopolsky et  
al., 200799 
 Normal / 
Overweight 
F+M Mixture 5.4+5 g 
creatine 
monohy-
drate 
6 months  -  ↓ ↑ Resistance   ↑ 
Diaz et al., 
2008101 
 Overweight / 
Obese 
F Mixture 1.8+0.4 
mg 
creatine 
picolinate 
12 weeks  - - - Endurance   ↔ 
(Continued) 
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Table 2.6. Continued 
References 
Subject 
 
CLA Supplementation  Resultsd   Muscle Metabolism  
Characteristic Gendera Formb Dosagec Duration BW BFM LBM Exercise Type 
Energy 
Expendituree Biomarkers
f
 
Exercise 
Outcome 
Cornish et al., 
2009106 
Obese F+M Mixture 4.3+9g 
creatine 
mono-
hydrate+
36g 
whey 
protein 
5 weeks  - - ↑ Resistance   ↑ 
Michishita et 
al., 2010207 
  Normal / 
Overweight 
F+M Mixture 1.6+1.52g 
amino 
acids 
12 weeks  - -  Resistance    
Chen et al.,  
2012109 
 Overweight / 
Obese 
F+M Mixture 1.7 12 weeks  ↓ ↓ - Resistance   ↔ 
Macaluso et al., 
2012110 
 Normal / 
Overweight 
M Mixture 4.8 3 weeks  - - - Resistance  ↑ Testosterone 
in serum 
↑ 
Bulut et al.,  
2013141 
Overweight M Mixture 3.0 4 weeks  - - - Endurance    
Jenkins et  
al., 2014215,216 
 Normal / 
Overweight 
M Mixture 5.63 6 weeks    Endurance ↔ PWCFT 
↔ VO2 max 
↔ GET 
↔ RCP 
 ↔ 
Tsao et al., 
2015154 
 Normal M Mixture 3.8 8 weeks  -   Endurance ↔ RMR ↑ Glycogen 
resynthesis / 
↑ GLUT4 
 
aF, female; M, male. 
bMixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer. 
cDosage (%) means a designated weight percentage of CLA in diet. 
dBW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease. 
eGET, gas exchange threshold; PWCFT, physical working capacity at the fatigue threshold; RCP, respiratory compensation point; RMR, resting metabolic rate; VO2 max, 
maximal oxygen uptake↔, no change. 
fGLUT4, glucose transporter type 4.  
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skeletal muscle energy metabolism. 
 
2.4 Literature Review Conclusion and Project Rationale 
 The literature review has discussed that CLA induces a decrease of body fat and an 
increase of lean body mass via various regulatory mechanisms. To date, most mechanistic studies 
of CLA on body composition change have been focused on adipocyte metabolism in adipose 
tissue. However, a growing number of studies highlighting the importance of CLA’s effect on 
skeletal muscle metabolism indicate that CLA supplementation may affect skeletal muscle 
metabolism representative to increased energy expenditure and enhanced physical activity. 
However, the underlying mechanism of how CLA modulates skeletal muscle metabolism has not 
been fully discovered. Thus, it is important to investigate the mechanistic study of CLA on 
skeletal muscle metabolism including previously well-established signaling pathways such as 
mitochondrial biogenesis and muscle fiber type transformation via the AMPK/SIRT1-PGC-1α-
PPARδ signaling cascade. 
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CHAPTER 3 
OBJECTIVES OF THE PROJECT 
The long-term goal is to develop prevention and/or treatment strategies for obesity and 
its related pathologies. The objective of this project is to uncover the mechanisms of CLA on 
muscle metabolism. The central hypothesis is that CLA targets the AMP-activated protein kinase 
(AMPK) signaling pathway and subsequently the underlying downstream signaling cascades 
associated with skeletal muscle metabolism. The rationale of the proposed research is that by 
understanding factors contributing to skeletal muscle and physical activity, we will be able to 
direct more efficient prevention strategies for obesity and associated chronic diseases in the 
future. 
The project aims are as follows: 
Specific Aim 1: Determine molecular targets of CLA’s effects on muscle metabolism in in 
vitro model: The objective of this project is to determine the key molecular mediators of CLA’s 
effects on muscle metabolism. The hypothesis to be tested is that CLA modulates AMPK, which 
can affect PPARγ coactivator 1α (PGC-1α), and activates the underlying downstream signaling 
cascades including mitochondrial biogenesis.  
Specific Aim 2: Determine the effects of CLA on physical activity and physiological changes 
in skeletal muscle in in vivo models: The objective of this is to determine if CLA influences 
voluntary activity and/or endurance exercise capacity in mice through the modulation of 
molecular markers in skeletal muscle metabolism. Two hypotheses to be tested are [1] CLA 
elicits improved voluntary activity by promoting mitochondrial biogenesis via the modulation of 
AMPK signaling pathway and [2] CLA and endurance exercise synergistically improves muscle 
metabolism by activating mitochondrial biogenesis and muscle fiber type transformation, leading 
to the enhancement of endurance capacity. Specifically, the first hypothesis is tested with two 
experimental designs targeting adulthood and childhood obesity.  
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CHAPTER 4 
CONJUGATED LINOLEIC ACID (CLA) STIMULATES MITOCHONDRIAL 
BIOGENESIS SIGNALING BY THE UPREGULATION OF PPARγ 
COACTIVATOR 1α (PGC-1α) IN C2C12 CELLS 
 
4.1 Introduction 
Skeletal muscle and the corresponding metabolic contributions play a critical role in 
maintaining homeostasis in the human body. Skeletal muscle metabolism includes adaptive 
responses to physical activity on glucose uptake, fatty acid oxidation, mitochondrial biogenesis 
and muscle fiber type shift.177 It is known that these adaptive responses of skeletal muscle involve 
a number of regulators, among them AMP-activated protein kinase (AMPK) is the most well-
known molecular target of exercise in skeletal muscle.217 During muscular adaptive responses, 
AMPK increases ATP production by controlling a number of transcriptional genes or proteins, 
including peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α), peroxisome 
proliferator-activated receptors (PPARs) and mitochondria-related proteins. These signaling 
cascades play an important role in improving muscle metabolism.5 
 Mitochondrial biogenesis is one of the adaptive responses in skeletal muscle and is the 
process of new mitochondrial formation resulting in direct improvement of energy production 
through increasing capacity of respiratory components.218,219 It has been reported that impaired 
mitochondrial biogenesis contributes to obesity and related diseases, such as diabetes and 
cardiovascular disease through mitochondrial dysfunction and resulting lipid accumulation in 
skeletal muscle.220 PGC-1α is known as the primary simulator of mitochondrial biogenesis. 
Activated PGC-1α subsequently triggers upregulation of nuclear respiratory factors (NRF-1 and -
2) and mitochondrial transcription factor A (Tfam), wherein NRF-1 and -2 play roles in the 
expression of a number of nuclear-encoding mitochondrial proteins and Tfam controls 
mitochondrial DNA replication and transcription. In turn, these nuclear-encoded markers activate 
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mitochondrial proteins and antioxidant enzymes in mitochondria, resulting in mitochondrial 
biogenesis.221-224 
Conjugated linoleic acid (CLA) is a mixture of geometric and positional conjugated 
isomers of linoleic acid (LNA). CLA has shown a variety of beneficial effects such as anti-
cancer, anti-atherosclerosis, antioxidant, and anti-obesity.14 Previously it was reported that CLA 
improved voluntary activity and endurance capacity in mice.17,18 There was further support that 
modulation of skeletal muscle metabolism by CLA was mediated by increased PPARδ gene 
expression 225. In addition, it was previously reported that the c9,t11 CLA isomer induced the 
activation of AMPKα in C2C12 skeletal muscle cells,194 however, it was not clear whether CLA 
isomers control PGC-1α and subsequent mitochondrial biogenesis. Thus we investigated the role 
of CLA isomers on PGC-1α based on AMPK signaling pathway and mitochondrial biogenesis-
related biomarkers to determine its role on mitochondrial biogenesis using C2C12 cells, an 
established murine muscle cell line. 
 
4.2 Materials and Methods  
4.2.1 Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM) and horse serum (HS) were obtained 
from Invitrogen (Grand Island, NY). Penicillin/streptomycin mixture, fetal bovine serum (FBS), 
and bovine serum albumin (BSA) were purchased from Sigma Aldrich (St. Louis, MO). The 
linoleic acid with 99% purity was purchased from Nu-Chek Prep (Elysian, MN). The t10,c12 
CLA; c9,t11 CLA; and CLA mixed isomer (Mixture) were obtained from Natural Lipids 
(Hovdebygda, Norway). The purity of the t10,c12 CLA preparation was 94 % with 2% c9,t11 
isomer and 3% other conjugated linoleic acid isomers. The c9,t11 CLA preparation was 90% pure 
and consisted of 4% t10,c12 isomer, 2% other conjugated linoleic acid isomers and 3% oleic acid. 
The CLA mixture was 80.7% CLA composed of 37.8% c9,t11, 37.6% t10,c12 and 5.3% other 
CLA isomers and 13.7% oleic acid, 3.2% stearic acid, 0.4% palmitic acid and 0.2% linoleic acid. 
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Rabbit anti-phosphorylated AMPKα and rabbit anti-AMPK, voltage-dependent anion channel 
(VDAC) and superoxide dismutase 2 (SOD2) antibodies were obtained from Cell Signaling 
(Berberly, MA). Rabbit anti-PGC-1α, sirtuin 1 (SIRT1), PPARδ, NRF-1, Tfam, cytochrome c 
(Cyt C), subunit IV of cytochrome c oxidase (COX IV), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and β-actin were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). Horseradish peroxidase-conjugated goat anti-rabbit IgG antibody was obtained 
from Boston Bioproducts Inc. (Ashland, MA). Other chemicals were purchased from either 
Fisher Scientific (Pittsburg, PA) or Sigma Aldrich (St. Louis, MO). 
 
4.2.2 C2C12 Cell Culture 
C2C12 mouse myoblasts (CRL-1772™) were obtained from American Type Culture 
Collection (Manassas, VA). C2C12 myoblasts were maintained in DMEM containing 10% (v/v) 
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in humidified 95% air and 5% CO2 
atmosphere. For differentiation the culture medium was switched to DMEM with 2% (v/v) heat-
inactivated horse serum when myoblasts were 90% confluent. The differentiation medium was 
subsequently replaced with fresh medium every two days. After 6 days of differentiation, 
myotubes were treated with fatty acids as fatty acid-albumin complexes as previously described.27 
Doses and time of treatment are indicated in each figure legend. All treatments included 50 µM 
fatty acid free albumin. Concentrations of CLA used reflect the serum levels of CLA after 
supplementing 0.5% CLA for 4 weeks in rats or supplementing 0.8-3.2 g per day for 2 months in 
humans, which ranged from 23 to 200 µM.27,226 Effects of these fatty acids on cell viability were 
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphnyltetrazolium bromide (MTT) based 
assay.227 No significant differences in cell viability were observed in any treatments (data not 
shown). 
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4.2.3 Western Blot Analysis 
The adherent cells were harvested and then lysed with lysis radioimmuno precipitation 
assay (RIPA) (50 mM Tris-HCl, 10 Mm NaCl, 5 Mm MgCl2, and 0.5% NP-40, pH 8.0) buffer 
(Boston Bioproducts Inc., Ashland, MA) containing protease inhibitor cocktail (Sigma Aldrich, 
St. Louis, MO) and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL) on ice for 30 
min, and centrifuged at 12,000g for 20 min at 4°C. Protein concentration of cell lysate was 
determined using the DC protein assay kit (Bio-Rad, Hercules, CA). The lysates were separated 
by a 6-15% (w/v) sodium dodecyl sulfate-polyacrylamide gel, transferred to a polyvinylidene 
fluoride (Millipore, Bedford, MA). After blocking for 1 h at room temperature (RT), the 
membrane was incubated with the primary antibody in TBS-T containing 5% BSA at 4°C 
overnight. The membrane was treated with horseradish peroxidase-conjugated goat anti-rabbit 
IgG antibody for 1 h at RT. Detection was performed using the enhanced chemiluminescence 
solution (Bio-Rad, Hercules, CA) with an Image Station 4000MM (Carestream Health, New 
Heaven, CT). GAPDH or β-actin intensity was used for an internal control to normalize protein 
content of each sample. Image J software provided by NIH was used to quantify the results. 
 
4.2.4 Quantitative Analysis of Mitochondrial DNA (mtDNA) 
Mitochondrial DNA copy number was determined based on method previously 
described.228 Total genomic DNA (gDNA) including mtDNA was purified using Puregene® core 
kit (Qiagne, Gaithersburg, MD) as described in the manufacturer’s protocol. NADH 
dehydrogenase subunit 1 (ND1, Mm04225274_s1) and 18S rRNA (Rn18s, Mm03928990_g1) 
with predesigned TaqMan gene expression assay kits were used to represent the mtDNA and the 
nuclear DNA (nDNA), respectively. The DNA concentration was diluted to 100 ng/µl, and 1 µl of 
DNA was used as a template for the real-time PCR. All reactions were carried out in triplicate 
with the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster, CA). The program of 
reaction was 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min 
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at 60°C. Quantification of relative mtDNA copy number was assessed by a comparative Ct 
method based on analysis of the difference in threshold amplification between mtDNA and 
nDNA. 
 
4.2.5 Statistical Analyses 
All data in Figures 4.1-4.5 from three independent experiments were collected in 
triplicates. Data in Fig. 4.6 are from one experiment. Data in Figures 4.1-4.5 were analyzed by 
Two-way analysis of variance (ANOVA) as treatment and experiment as variables, and data in 
Figure 4.6 were analyzed by one-way ANOVA, followed by PROC MIXED with Least Square 
Means options of the SAS software for Windows release 9.2 (SAS Institute Inc., Cary, NC) on 
the W32_VSHOME platform. The experimental groups were compared by multiple comparisons 
based on the Dunnett’s test. Data are presented as mean ± S.E. P values < 0.05 are reported as 
statistically significant. 
 
4.3 Results  
4.3.1 Effect of CLA Isomers on AMPK Signaling Pathway in C2C12 Skeletal Muscle Cells 
Based on previous reports that CLA upregulated PPARδ and AMPK expressions,18,194,196 
we first determined the effect of CLA isomers on AMPK signaling pathway (Fig. 4.1). The 
relative expression levels of total AMPKα were not different in all treatments compared to 
control (Fig. 4.1B). However, treatments with the t10,c12 CLA isomer or the CLA mixture 
significantly upregulated phosphorylation of AMPKα compared to control (Fig. 4.1C). As a 
result, increased ratio of phosphorylated AMPKα to total AMPKα by the t10,c12 isomer and the 
CLA mixture were observed (Fig.4.1D). However, no differences were observed by either 
linoleic acid or the c9,t11 CLA isomer compared to control in these parameters. 
 Along with AMPK, SIRT1 is also known to be involved in activation of PGC-1α by 
deacetylation independent to AMPK.185 There were no differences in the expressions of SIRT1 by 
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all treatments (Fig.4.2). These data suggest that CLA, particularly the t10,c12 isomer, controls 
AMPKα to regulate PGC-1α, but not via SIRT1. 
 
4.3.2 Effect of CLA Isomers on PGC-1α Expression 
We next examined the effects of CLA isomers on the expressions of PGC-1α, which is one of the 
downstream target proteins of AMPK and also plays a central role in regulation of mitochondrial 
biogenesis.182 Both CLA isomers, c9,t11 and t10,c12, and the CLA mixture significantly 
increased the protein expression levels of PGC-1α compared to control (Fig. 4.3). Linoleic acid 
itself did not significantly increase expression of PGC-1α over control. These results suggest that 
CLA may stimulate mitochondrial biogenesis via PGC-1α-mediated signaling cascades. 
 
 
Figure 4.1 Effect of conjugated linoleic acid (CLA) isomers on protein expression levels of AMP-
activated protein kinase α (AMPKα) in C2C12 cells. 
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Figure 4.2 Effect of conjugated linoleic acid (CLA) isomers on the relative expression levels of 
sirtuin1 (SIRT1) in C2C12 cells. 
 
 
 
Figure 4.3 Effect of conjugated linoleic acid (CLA) isomers on peroxisome proliferator-activated 
receptor γ coactivator 1-α (PGC-1α) expression in C2C12 cells. 
 
4.3.3 Effect of CLA Isomers on Mitochondrial Biogenesis-related Biomarkers 
The effects of CLA on mitochondrial biogenesis were measured through PPARδ, NRF-1 
and Tfam primarily controlled by PGC-1α.229,230 The CLA mixture significantly increased 
expression of PPARδ compared to control, while the c9,t11 or t10,c12 isomer or linoleic acid did 
not show any significant effect compared to control (Fig. 4.4B). Among nuclear respiratory 
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factors (NRF-1 and -2), NRF-1 is more specifically related to mouse Tfam, we thus analyzed the 
expression level of NRF-1 instead of NRF-2.231 Both c9,t11 and t10,c12 CLA isomers 
significantly upregulated NRF-1 expression compared to control (Fig. 4.4C). Furthermore, 
expression of Tfam was significantly increased after treatments of all individual CLA isomers 
compared to control, while linoleic acid itself did not have any effect compared to control (Fig. 
4.4D). Collectively, these data from mitochondrial biogenesis-related biomarkers suggest that 
c9,t11 and t10,c12 CLA isomers may have a positive effect on mitochondrial biogenesis through 
modulating NRF-1 and Tfam. 
 
Figure 4.4 Effect of conjugated linoleic acid (CLA) isomers on mitochondria-related factors in 
C2C12 cells. 
 
4.3.4 Effect of CLA Isomers on Mitochondrial Content 
Overall mitochondrial relative content can be indirectly estimated by determining the 
expression levels of cytochrome c and COX IV located in the inner membrane of mitochondria 
and VDAC localized in the mitochondrial outer membrane.232,233 The c9,t11 CLA isomer 
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significantly increased the expression of cytochrome c (Fig. 4.5B). On the other hand, the t10,c12 
CLA isomer showed significantly increased VDAC expression compared to control (Fig. 4.5D). 
No significant effects by linoleic acid were observed on cytochrome c or VDAC. To assess 
mitochondrial function, we also measured the expression level of SOD2, manganese superoxide 
dismutase (MnSOD), which is one of the genes encoding mitochondrial protein in the inner 
mitochondrial matrix and protect mitochondria from reactive oxygen species.234 In this study, no 
significant effects were observed by any treatment on expression level of SOD2 (Fig. 4.5E). 
 
Figure 4.5 Effect of conjugated linoleic acid (CLA) isomers on mitochondrial content in C2C12 
cells. 
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 We further determined the ratio between mtDNA and nDNA as an indicator of 
mitochondrial replication. Both CLA isomers, c9,t11 and t10,c12, as well as the CLA mixture 
significantly increased the ratio mtDNA/ nDNA compared to control, whereas linoleic acid 
showed no significant difference over control (Fig. 4.6). Taken together, our observations indicate 
that both CLA isomers induce the increase of mitochondrial DNA replication, although 
mitochondrial components may be increased in isomer-dependent pathways. 
 
Figure 4.6 Effect of conjugated linoleic acid (CLA) isomers on mitochondrial DNA (mtDNA) 
copy number in C2C12 cells. 
 
4.4 Discussion 
In this study, we demonstrated that CLA activated several key biomarkers in 
mitochondrial biogenesis signaling cascade in C2C12 murine skeletal muscle cells. Of particular 
importance the c9,t11 and t10,c12 CLA isomers targeted PGC-1α and triggered the activation of 
downstream proteins such as NRF-1 and Tfam, as well as upregulating PPARδ (the CLA 
mixture), resulting in modulation in mitochondrial biogenesis. These results suggest that both 
CLA isomers stimulate mitochondrial biogenesis and this can help explain improved activity and 
endurance capacity in mice fed CLA reported in previous publications.17,18 
Several studies have demonstrated the effect of polyunsaturated fatty acids such as 
docosahexaenoic acid (DHA) and the t10,c12 CLA isomer on enhanced glucose uptake and fatty 
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acid β-oxidation through AMPK upregulation in murine skeletal cells.196,235,236 However, 
mechanisms of these polyunsaturated fatty acids on downstream signaling cascade from AMPK 
are not clear yet. It is reported that AMPK is required for regulation of PGC-1α in skeletal muscle 
and PGC-1α is the most promising target to regulate mitochondrial biogenesis.182,237 Moreover, 
PGC-1α-NRF-1/-2-Tfam cascade is generally accepted as mitochondriogenic pathway, even 
though there are various PGC-1α-dependent downstream cascades.229 Our results here support 
that CLA modulates PGC-1α via AMPK signaling cascades and resulting mitochondrial 
biogenesis-related molecular markers through PGC-1α-NRF-1-Tfam. In addition, lack of effects 
on SIRT1 by CLA is consistent with the previous reports that SIRT1 was not required for 
mitochondrial biogenesis through PGC-1α activation.238 However, we cannot conclude whether 
CLA directly targeted AMPK or acted indirectly via upstream regulators of AMPK such as liver 
kinase B1 (LKB1) and Ca2+/calmodulin-dependent protein kinase (CaMK) with current results. 
Therefore, additional studies are needed to confirm the primary targets of CLA for this activity, 
particularly upstream regulators of AMPK. 
 The c9,t11 CLA is the predominant natural CLA form comprising approximately 80% of 
the total isomers in dairy and meat products from ruminants, while synthetic CLA for commercial 
preparations is typically a 50:50 mixture of c9,t11 and t10,c12 CLA isomers.15 Most biological 
effects of CLA are known to be results of independent or additive effects, however, there are few 
reports that these two CLA isomers interact.142 For muscle metabolism, previous studies report on 
the effects of c9,t11, t10,c12 CLA and CLA mixed isomers on AMPK in skeletal muscle 
cells.194,195 Our data illustrated that the t10,c12 isomer and the CLA mixture upregulated AMPK 
activity independent of the c9,t11 isomer. This is inconsistent with observations by Qin et al.194 
that the c9,t11 isomer increased the expression of AMPK in a dose and time dependent manner. 
This discrepancy may be in part due to methodological differences; they examined only c9,t11 
isomer treatment (without t10,c12 or CLA mixed isomers) compared to control and all their 
treatments were combined with palmitate. In addition, our observations were consistent with the 
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results of Mohankumar et al.195 that t10,c12 but not c9,t11 CLA stimulated phosphorylation of 
AMPK in a time-dependent manner, although they used a different cell line (L6 myotube) and 
shorter incubation time (30 min). 
In the current results, we observed both CLA isomers increased expression of PGC-1α, 
although only the t10,c12 CLA isomer, but not the c9,t11 isomer, activated AMPK (Fig 4.1). 
Previously Parra et al.198 reported that a commercial CLA mixture upregulated PGC-1α gene 
expression in C57BL/6J gastrocnemius muscle although it is not clear if both isomers have effects 
on PGC-1α in this study. Thus, it is possible that there is an additional mechanism contributing to 
the c9,t11 isomer’s effects on PGC-1α, possibly via LKB1 and CaMK.183 
PPARδ is abundant in skeletal muscle and is a primary target gene for preventing 
obesity and improving physical activity through modifying muscle morphology and enhancing 
oxidative capacity.192 Previously it was reported that the t10,c12 CLA isomer upregulated mRNA 
level of PPARδ in trained 129 Sv/J mice gastrocnemius muscle.18 In the current study, the CLA 
mixture, but not the c9,t11 or t10,c12 isomer, showed significant differences in PPARδ 
expression compared to control. This observation is similar to a study by Oraldi et al.199 that the 
CLA mixed isomers increased both transcriptional and translational levels of PPARδ in C2C12 
cells. It is not clear why the individual CLA did not significantly influence expression of PPARδ 
in the current study. These discrepancies may derive from differences in experiments, in vivo vs. 
in vitro, and the presence or absence of an exercise regime for the in vivo study. Although a few 
methods mimicking exercise training, for example electrical pulse stimulation, are used for in 
vitro testing, this model still has unavoidable limitations. 
 We also tested effects of CLA isomers on the expression levels of NRF-1 and Tfam 
(both known to modulate mitochondrial biogenesis221) as downstream regulators of PGC-1α. 
Tfam activation regulates the expression of mitochondrial DNA encoded oxidative respiratory 
phosphorylation proteins, resulting in the induction of increased mitochondrial contents and 
functions 239. In this study, CLA isomers induced NRF-1 activation as well as Tfam, a 
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downstream marker from NRF-1, which was significantly activated by both c9,t11 and t10,c12 
CLA isomers. This suggests that CLA may increase mitochondrial biogenesis via the universal 
signaling cascade, PGC-1α-NRF-1-Tfam,221 and is further supported by the finding that 
mitochondrial DNA copy number significantly increased after CLA treatments (Fig. 4.6). 
In the current study, we tested effects of CLA isomers on several mitochondrial markers, 
cytochrome c, COX IV and VDAC. The expression levels of cytochrome c, COX IV and VDAC 
indirectly represents whether tissues or cells are undergoing mitochondrial biogenesis.232 In 
particular, cytochrome c is involved in oxidative capacity through phosphorylation, while VDAC 
is known to be linked to mitochondrial dysfunction and aging as well.240 Our results suggest that 
the c9,t11 isomer increased expression of cytochrome c, while t10c12 isomer increased 
expression of VDAC. The former observation is consistent with Mollica et al.241 that the c9,t11 
isomer, but not the t10,c12 isomer, induced higher cytochrome c activity in Wistar rats. There are 
currently no reports of CLA’s effect on VDAC, however, it was reported that other 
polyunsaturated fatty acids, DHA and eicosapentaenoic acid (EPA), did not increase VDAC 
expression in male Wistar rats.242 This is the first report that t10,12 CLA significantly increase 
VDAC expression in C2C12 cells, which may provide evidence to have more mitochondria. Also 
our results suggest that individual CLA isomers might selectively activate mitochondrial proteins 
associated with mitochondrial biogenesis, resulting in stimulation of mitochondriogenic 
signaling. In addition, although cytochrome c, COX IV and VDAC represent mitochondrial 
components as an indirect marker for mitochondrial biogenesis, we cannot rule out the possibility 
that CLA may influence other mitochondrial-related factors, such as COX I, II and III subunits 
and ATP synthase subunits in C2C12 myotubes.243  
PGC-1α is also involved in the induction of ROS-detoxifying enzymes such as SOD2 in 
mitochondria.224 The c9,t11 CLA isomer increased the mRNA level of SOD2 in earlier studies of 
CLA-treated in Sprague-Dawley rats and THP-1 macrophages,152,244 although we did not observe 
any differences due to individual CLA isomers on SOD2. These discrepancies may result from 
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differences in experimental models used, i.e. dietary supplement to animals with exercise and 
cells with an oxidative stressor.  
In conclusion, both CLA isomers were shown to activate PGC-1α, which was linked with 
upregulation of mitochondrial biogenesis. It is likely that the t10,c12 isomer activates PGC-1α 
through AMPK phosphorylation and the c9,t11 isomer stimulates PGC-1α via another 
undetermined pathway as c9,t11 isomer does not activate phosphorylated AMPK. Both c9,t11 
and t10c12 CLA isomers enhance the expression of NRF-1 and Tfam. Also the CLA mixture 
improves PPARδ expression. It is supporting that all CLA treatments significantly increase 
mitochondrial DNA replication. Taken together, CLA engages the mitochondrial biogenesis 
process through modulating PGC-1α-NRF-1-Tfam cascade without any isomer interaction. 
Overall, CLA may play a role as a stimulator of mitochondrial biogenesis. 
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CHAPTER 5 
CONJUGATED LINOLEIC ACID (CLA) IMPROVES MUSCLE METABOLISM 
VIA STIMULATING MITOCHODNRIAL BIOGENESIS SIGNIALING IN 
GENETICALLY INDUCED INACTIVE ADULT-ONSET OBESE MICE 
 
5.1 Introduction 
Reduced energy expenditure, particularly associated with lack of physical activity, plays a 
significant role in weight gain.245 However, overall physical activity can be influenced by 
complex issues, and thus make it difficult to use as universal means to control/prevent obesity.246 
Previously nescient helix-loop-helix 2 wild type (N2KO) mouse model has been established, 
where these animals exhibit reduced activity at a certain age, 7-10 weeks old, without 
hyperphagia during preobese period. Targeted deletion of the Nhlh2 transcription factor 
expressed in the hypothalamus precedes adult-onset obesity in mice, contributing to a disruption 
of the hypothalamic-pituitary axis.247,248 Thus, N2KO mice represent an animal model that mimics 
induction of adult-onset obesity, making it particularly useful to investigate any compounds that 
target activity in these animals. 
Conjugated linoleic acid (CLA) is a mixture of geometric and positional conjugated 
isomers of linoleic acid. The effects of CLA have been previously demonstrated as to influence 
on development of cancer and atherosclerosis, as well as preventing osteoporosis and modulating 
immune responses.13,14 Moreover, CLA has drawn special attention in the last two decades for its 
anti-obesity effect through various mechanisms, such as regulation of energy and lipid 
metabolism, adipogenesis, inflammation and adipocyte apoptosis.15,16 In addition, it was reported 
that CLA improved voluntary activity and endurance capacity in animal models, including N2KO 
animals, and CLA modulated energy metabolism, especially uncoupling protein 2 (UCP2) and 
peroxisome proliferator-activated receptor δ (PPARδ) in skeletal muscle.17,18 However, it is 
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currently not fully understood how CLA influences skeletal muscle metabolism, including 
mitochondrial biogenesis. 
Mitochondrial biogenesis is composed of complex long-term adaptive responses in skeletal 
muscle.249 It is known that mitochondrial biogenesis is important for endurance capacity but also 
plays a significant role in proper weight management.10,220 In fact, CLA isomers, cis-9,trans-11 
and trans-10,cis-12, stimulated the key molecular markers involved in mitochondrial biogenesis 
and increased mitochondrial DNA copy number.250 Also, it was previously reported that CLA 
increased voluntary activity and endurance capacity as well as reduced obesity. Thus, we 
investigated the role of CLA on skeletal muscle energy metabolism and mitochondrial biogenesis 
using N2KO mice to understand its underlying mechanisms on weight control. 
 
5.2 Materials and Methods 
5.2.1 Materials 
CLA was provided by Natural Lipids Ltd. AS (Hovdebygda, Norway). The CLA content 
of the preparation used was 80.7%. CLA consisted of 37.8% cis-9,trans-11, 37.6% trans-10,cis-
12 and 5.3% other CLA isomers and the remainder of the preparation was 13.7% oleic acid, 3.2% 
stearic acid, 0.4% palmitic acid and 0.2% linoleic acid. Semi-purified powdered diet (TD07518, 
95% basal mix) was purchased from Harlan Laboratories (Madison, WI). Serum triacylglyceride 
(TG), glucose, and total cholesterol assay kits were purchased from Genzyme Diagnostics 
(Charlottetown, PE, Canada). DC protein assay kit was from Bio-Rad (Hercules, CA). Rabbit 
antibodies for phosphorylated AMP-activated protein kinase α (AMPKα), AMPKα, voltage-
dependent anion channel (VDAC) and superoxide dismutase 2 (SOD2) were obtained from Cell 
Signaling (Berberly, MA). Rabbit antibodies for peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), PPARδ, nuclear respiratory factor 1 (NRF-1), 
mitochondrial transcription factor A (Tfam), cytochrome c (Cyt C), cytochrome c oxidase subunit 
4 (COX IV), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin were purchased 
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from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish peroxidase-conjugated goat 
anti-rabbit IgG antibody was from Boston Bioproducts Inc. (Ashland, MA). Other chemicals used 
were purchased from either Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific (Pittsburg, 
PA). 
 
5.2.2 Animal and Diet 
All animal work was done in compliance with the Institutional Animal Care and Use 
Committee at the University of Massachusetts, Amherst. 129Sv/J heterozygous for Nhlh2 male 
and female mice between 8 and 52 weeks of age were used as breeders to prepare for wild type 
and Nhlh2 knock-out offspring (N2KO). Based on the results from genotyping at weaning,247 
eight female wild type and six N2KO mice were placed in wire-bottomed cages with a 12:12 h 
light:dark cycle. During a 2-week acclimation period, mice were fed a control diet (20 w/w% fat) 
and were subjected to baseline test for glucose tolerance and voluntary movement. At the end of 
the adaptation period, animals were divided into two groups per each genotype based on their 
body weight. Either control (high-fat, 20 w/w% fat) or 0.5% CLA containing high-fat diet was 
provided for 10 weeks. Diets and water were available ad libitum. The diet composition is shown 
in Table 5.1. Body weight and food intake were monitored weekly. At the end of study, the mice 
were fasted for 4 h, and sacrificed by CO2 asphyxiation. Blood was collected by cardiac puncture 
and internal organs (liver, heart, kidney, spleen, adipose tissues including parametrial, 
retroperitoneal and mesenteric fats and gastrocnemius muscle) were also weighed. 
 
5.2.3 Voluntary Movement Measurement (Non-exercise Physical Activity Test) 
Voluntary movement was recorded using LoliTrack Quatro Video Tracking Software 
Version 1.0 (Loligo Systems, Tjele, Denmark) with a high-resolution camera supported to 
monitor under dim light. Animals were individually placed into a cage during the dark cycle  
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Table 5.1. Composition of experimental diet for control and conjugated linoleic acid (CLA) groups. 
Ingredient g/kg 
Casein, ‘vitamin-free’ tested 169.1 
L-Cystine   2.2 
Sucrose 100 
Cornstarch 288.5 
Maltodextrin 132 
Cellulose  50 
Soybean oil 195 
CLA or Soybean oil   5 
Mineral mix, AIN-93M-MX (TD 94049)  42.8 
Vitamin mix, AIN-93-VX (TD 94047)   12.4 
Choline bitartrate   3 
tert-Butylhydroquinone   0.04 
Total 1,000 
 
(5:00pm-5:00am) once biweekly with free access to diet and water (provided as HydroGel, 
Clear H2O, Portland, ME). The cage (30 × 46 × 40 cm) used for activity monitoring is larger than 
the typical cage to measure proper movement, since the small cage is known to limit voluntary 
movements.251 Movement data for 8 h (7:00pm-3:00am) was analyzed excluding the first 2 h 
(5:00pm-7:00pm) of early phase and 2 h (3:00am-5:00am) of late phase, due to early adaption 
and due to lack of movement, respectively. 
 
5.2.4 Serum Parameters 
Serum was separated by centrifugation at 3,000 g for 20 min at 4°C. Serum samples 
were used for determination of TG, glucose and total cholesterol using commercial kits following 
by the manufacturer’s instruction. 
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5.2.5 Glucose Tolerance Test 
Intraperitoneal glucose tolerance test (IGTT) was performed every four weeks as 
described previously252 with some modification. Glucose levels were measured using a blood 
glucose meter, Advocate Redi-Code+ (Advocate Meters Inc., Dorado, Puerto rico). All mice were 
fasted for 6 h before IGTT, and glucose levels were monitored from the tail vein at 0 min for 
baseline measurement. Then a 30% glucose solution (2.0g glucose/kg body weight) was 
administered by intraperitoneal injection. Blood glucose levels were monitored at 15, 30, 60, 90 
and 120 min post glucose injection. The areas under the curve (AUC) were calculated using 
SigmaPlot 11.0 (Systat Software, Inc., San Jose, CA). 
 
5.2.6 Western Blot Analysis 
Gastrocnemius skeletal muscle tissue was ground with liquid nitrogen, prepared for 50 
mg aliquots and stored at -80°C until analysis. Each sample was homogenized in lysis 
radioimmune precipitation assay (RIPA) (50 mM Tris-HCl, 10 mM NaCl, 5 mM MgCl2, and 
0.5% NP-40, pH 8.0) buffer (Boston Bioproducts Inc., Ashland, MA) containing protease 
inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and phosphatase inhibitor cocktail (Thermo 
Scientific, Rockford, IL) and then lysed on ice for 2 h, and centrifuged at 12,000g for 20 min at 
4°C. Protein concentration of tissue lysate was determined using the DC protein assay kit. The 
lysates were separated by an 8-15% (w/v) sodium dodecyl sulfate-polyacrylamide gel and 
transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA). After blocking for 
1 h at room temperature (RT), membranes were incubated with appropriate primary rabbit 
antibodies in 0.05% Tween-20 in tris-buffered saline (TBS-T) containing 5% bovine serum 
albumin at 4°C overnight. After washing, membranes were treated horseradish peroxidase-
conjugated goat anti-rabbit IgG antibody for 1 h at RT. Detection was performed using the 
Enhanced Chemiluminescence solution (Bio-Rad, Hercules, CA) with an Image Station 4000MM 
(Carestream Health, New Heaven, CT). GAPDH or β-actin intensity was used for an internal 
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control to normalize protein content of each sample. Image J software was used to quantify the 
results. 
 
5.2.7 Statistical Analyses 
Data were analyzed by two-way analysis of variance (ANOVA) followed by PROC 
MIXED with Least Square Means options of the SAS software (Version 9.3, SAS Institute Inc., 
Cary, NC, USA). For the body weight, food intake, voluntary movement and glucose tolerance 
test, two-way ANOVA and repeated measures with PROC MIXED were performed. In the 
repeated measures using PROC MIXED, we found that the assumption of constant variance did 
not appear to hold for the trend of voluntary movement. Thus, data were converted into 
logarithm-scale and used for analysis. For internal organ, adipose tissue weight, serum parameters 
and the log-transformed relative protein expression level data two-way ANOVA with PROC 
MIXED were used. The Tukey-Kramer’s method in SAS was used for the multiple comparisons 
among the experimental groups. Data are shown as the mean ± S.E. P values less than 0.05 are 
reported as statistically significant. 
 
5.3 Results 
5.3.1 Body Weights and Food Intake 
Body weight and food intake data are shown in Figure 5.1A and 1B. N2KO mice started 
to show greater body weight than wild type mice at week 5 (10-week-old) and maintained this 
trend to the end of the experiment (overall genotype effect, P < 0.0001). Furthermore, CLA fed 
animals showed significant reduction in body weight (overall CLA effect, P = 0.042). Greater 
effects of CLA on body weight were observed in N2KO animals compared to wild type animals, 
when significance was observed starting at week 6 between N2KO control and N2KO CLA 
groups (Fig. 5.1A). No significant differences were observed in food intakes between any of 
groups (Fig. 5.1B). 
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5.3.2 Tissue Weights 
Total adipose tissue weight including parametrial, mesenteric, and retroperitoneal 
adipose tissue, liver, heart, kidney, spleen and gastrocnemius skeletal muscle tissue weights are 
shown in Table 5.2. N2KO control animals had the most adipose depots among all treatment  
 
Figure 5.1 Effect of conjugated linoleic acid (CLA) on body weight (A) and food intake (B) in 
wild type and N2KO mice. 
 
groups. Adipose tissue weights except mesenteric fat were significantly different by genotype, 
while significant interaction between diet and genotypes were observed in mesenteric adipose 
tissue weights. Only retroperitoneal fat weights but not others showed significantly difference by 
CLA supplementation (P = 0.0055).  
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The gastrocnemius skeletal muscle weights were significantly increased with CLA (P = 
0.0282), along with significant genotype effects (P < 0.0001). No interactions were observed for 
diets and genotypes in muscle weights. Both genotype and CLA had significant effects on kidney 
weights. Liver, heart and spleen weight were influenced by CLA significantly, but not by 
genotypes. 
 
Table 5.2. Effects of conjugated linoleic acid (CLA) on organ weights in wild and N2KO mice. 
 
Values represent means ± S.E. (n = 3-4). a-bMeans with different superscripts within the same row are 
significantly different (P < 0.05). P-values in table are from two-way ANOVA. N2KO, nescient helix-loop-
helix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant. 
 
 
5.3.3 Voluntary Movement Measurement (Non-exercise Physical Activity Test) 
Effects of CLA on physical activity were determined by measuring voluntary movement 
(non-exercise physical activity) biweekly (Fig. 5.2A-F). Data in Figures 5.2A-F were plotted over 
time (Fig. 5.2G-I). Data were represented as total (19:00-03:00) as well as two different time 
periods, early (19:00-23:00) and late (23:00-03:00). As reported previously,205,253 N2KO mice 
showed significantly decreased travel distances compared to wild type animals over time (overall 
genotype effects, P < 0.0001), meanwhile CLA treatment significantly increased total  
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Figure 5.2 Effect of conjugated linoleic acid (CLA) on voluntary movement (non-exercise 
physical activity) in wild type and N2KO mice. 
 
travel distance (P = 0.0172). No interactions among genotype, diet and time were observed. 
Intriguingly, voluntary movements during the late phase in control diet-fed mice were 
significantly reduced compared to CLA-diet groups (P = 0.0022), whereas during the early phase 
there was no significant CLA effect on travel distances in all treatment groups. In Figures 5.2G-I, 
it was evident that control N2KO mice showed declining activity in total as well as early and late 
phase over time, while CLA-fed N2KO mice either did not display reduced activity or slightly 
increased voluntary movement during the same time period. 
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5.3.4 Glucose Tolerance Test 
To evaluate whether CLA treatment affects glucose homeostasis, we completed glucose 
tolerance tests every four weeks (Fig. 5.3). There were no significant differences among all 
treatment groups at each time point. However, there were significant overall time effects (P < 
0.0001), which suggests potential impaired glucose tolerance due to high-fat diet over ageing in 
these animals regardless of diet or genotype effects. 
 
Figure 5.3 Effect of conjugated linoleic acid (CLA) on glucose tolerance in wild type and N2KO 
mice. 
 
5.3.5 Serum Parameters 
Results of serum parameters are shown in Table 5.3. N2KO animals had higher levels of 
serum TG than wild type mice (P = 0.0003), with overall CLA effects on TG observed (P = 
0.0408). No interactions were observed for TG on genotypes and CLA effects. Consistent with 
glucose tolerance results during the experimental period, no difference in the levels of glucose 
was observed among all experimental groups. Significant interaction between genotypes and 
CLA was observed in total cholesterol level (P=0.0080). 
 
56 
Table 5.3. Effects of conjugated linoleic acid (CLA) on serum parameters in wild and N2KO mice. 
 
Values represent means ± S.E. (n = 3-4). a-bMeans with different superscripts within the same row are 
significantly different (P < 0.05). P-values in table are from two-way ANOVA. N2KO, nescient helix-loop-
helix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant. 
 
5.3.6 Effects on Muscle Metabolism 
To determine whether CLA treatment influences skeletal muscle metabolism, we 
investigated the effect of CLA on AMPK signaling pathway (Fig. 5.4A and B). There were no 
differences in all treatments in the relative expression levels of total AMPKα, a master sensor to 
maintain energy homeostasis. However, significant effects of CLA on phosphorylation of 
AMPKα (the active form of AMPKα) compared to the control groups were observed (P = 0.0291 
for overall CLA effect). As a result, increased ratio of phosphorylated AMPKα to AMPKα was 
shown in CLA-fed animals (P = 0.024 for overall CLA effect). Another key biomarker, SIRT1, a 
NAD-dependent deacetylase inducing PGC-1α activation, was not significantly different in all 
treatment groups. However, expression of PGC-1α, a master regulator of mitochondrial 
biogenesis, was increased slightly in N2KO CLA animals compared to respective control, 
although it did not reach significance (Fig. 5.4B). 
 
5.3.7 Effects on Mitochondrial Biogenesis-related Factors 
Based on the evidence that CLA potentiates activation of AMPKα and PGC-1α in 
N2KO mice in Fig. 5.4, we evaluated whether CLA treatment was involved in mitochondrial 
biogenesis in the gastrocnemius muscle. Mitochondrial biogenesis plays a key role in increasing 
oxidative capacity, thus reduces muscle fatigue, resulting in prolonged endurance capacity.249 We 
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Figure 5.4 Effect of conjugated linoleic acid (CLA) on protein expression of AMP-activated 
protein kinase (AMPK), SIRT1, and PGC-1α from the gastrocnemius muscle in wild type and 
N2KO mice. 
 
have tested PPARδ, NRF-1 and Tfam in the gastrocnemius muscle, all of them are well-known 
markers for mitochondrial biogenesis that are primarily controlled by PGC-1α.229,230,254 As 
expected, supplementation with CLA significantly increased the expression levels of PPARδ 
compared to control-fed animals (P = 0.0215 for overall CLA effect), which is a marker 
associated in mitochondrial biogenesis as well as muscle type transformation. The expression 
levels of NRF-1, a regulator to mediate nuclear-encoding mitochondrial proteins, were not 
different in all experimental groups. Expression of Tfam, an important regulator for 
mitochondrial DNA replication and transcription, was upregulated by CLA-supplementation in 
comparison to controls (P = 0.0225 for overall CLA effect) in both genotype animals (Fig. 5.5A 
and B). 
We further investigated expression levels of mitochondrial proteins, cytochrome c and 
COX IV located in the inner membrane of mitochondria and VDAC localized in the outer 
mitochondrial membrane.232 Also, we measured expression of manganese superoxide dismutase 
(SOD2), which encodes a mitochondrial matrix protein and protects mitochondria from reactive 
oxygen species, to assess mitochondrial function.234 Among them cytochrome c protein levels 
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Figure 5.5 Effect of conjugated linoleic acid (CLA) on mitochondrial biogenesis-related factors 
from the gastrocnemius muscle in wild type and N2KO mice. 
 
were significantly increased in wild type animals (P = 0.0069 for overall genotype effect). The 
expression levels of VDAC slightly increased in CLA-fed mice compared to control groups. No 
significant differences were observed in COX IV and SOD2 (Fig. 5.6A and B). 
 
Figure 5.6 Effect of conjugated linoleic acid (CLA) on mitochondrial content and function from 
the gastrocnemius muscle in wild type and N2KO mice. 
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5.4. Discussion 
In the current study, we have demonstrated that CLA treatment prevents body weight 
gain and improves voluntary movements through modulating the key molecular markers related 
to muscle metabolism via stimulating mitochondrial biogenesis signaling in adult-onset inactivity 
induced obese mice. Of particular importance CLA-fed mice were shown to activate AMPKα, 
PGC-1α, and subsequently upregulate mitochondria-related molecular markers, such as PPARδ 
and Tfam in both wild type and N2KO mice. These observations further support that CLA 
supplementation helps improve physical activity, and change body composition including 
increased lean body mass in previous animal studies.15,17,27,31,63,205 This is the first report that CLA 
treatment may lead to preventing the development of obesity in adult-onset inactivity induced 
obese mice by stimulating mitochondrial biogenesis. 
Mitochondria is one of the key cellular compartments generating energy requires for 
cells and may play a significant role in maintaining energy balance and contribute to attenuating 
the development of obesity. The process of formation of mitochondria, mitochondrial biogenesis, 
is a complicated process and regulated by numerous different upstream signals, however, it is 
well-established that PGC-1α is a primary master regulator of mitochondrial biogenesis.218,219,222 
Activated PGC-1α subsequently triggers upregulation of nuclear and mitochondrial genes and 
proteins such as PPARδ, NRF-1 and -2, and Tfam, which lead to mitochondrial biogenesis.229 It is 
further supported that PGC-1α is involved in physical activity and promotes the formation of 
oxidative slow-twitch muscle fibers resulting in enhanced endurance capacity and improved 
exercise tolerance.190,255 The current results suggest that CLA may potentiate mitochondrial 
biogenesis via PGC-1α, particularly in N2KO animals. Also increased voluntary activity levels 
resulting from CLA supplementation may have modulated muscle metabolism through the 
upregulation of PGC-1α expression. However, further confirmatory studies are needed, including 
changes of morphological and histological properties of skeletal muscles with regard to fiber type 
transformation from fast (glycolytic) to slow-twitch (oxidative). 
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To further understand whether increased PGC-1α activity with CLA was directly 
influenced or not, we further investigated the upstream activators of PGC-1α; phosphorylation by 
AMPKα and deacetylation by SIRT1 5. CLA treatment significantly upregulated the expression of 
phosphorylated AMPKα (active form of AMPKα) but not SIRT1 activity, suggesting that the 
influence of CLA on AMPKα activation is more important than that of SIRT1.194-196,238  
 Although PGC-1α facilitates various molecular events, PGC-1α-NRF-1/-2-Tfam and 
PGC-1α-PPARδ signaling cascade are important mitochondriogenic pathways.186,256 PPARδ plays 
a critical role in regulation of muscle fiber type transformation and improvement of endurance 
capacity by stimulating mitochondrial functions including mitochondrial biogenesis.192,257 It was 
previously reported that the trans-10,cis-12 CLA isomer increased mRNA expression level of 
PPARδ in exercise-trained 129 Sv/J mice gastrocnemius skeletal muscle.18 Consistently, the 
current results support that CLA supplementation upregulated PPARδ expression in both N2KO 
and wild type mice. 
 Alternatively, PGC-1α regulates NRF and Tfam. NRF-1 and -2 play significant roles in 
the expression of nuclear-encoding mitochondrial genes and proteins and Tfam controls the 
expression of mitochondrial DNA encoded oxidative respiratory phosphorylation proteins. Their 
activation results in increased mitochondrial mass and functions.239,258,259 In the current study 
CLA treatment activated Tfam, which is reported to be closely linked with activation of 
AMPKα.182,260 Taken together, the current results suggest that CLA promotes mitochondrial 
biogenesis through AMPKα-PGC-1α-PPARδ and/or -Tfam. 
 Upregulation of cytochrome c, a nuclear-encoded protein of the electron transport chain, 
has been previously reported in other food bioactive compounds, quercetin and isoflavones.260,261 
In this study, CLA supplementation resulted in increased cytochrome c, potentially mediated by 
increased upstream signaling pathway as described above. However, our current results cannot 
rule out the possibility that CLA may also influence other regulatory mechanisms for cytochrome 
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c, such as the early growth response gene-1 (EGR1), specificity protein 1 (Sp1) and 
thrombospondin-1 receptor CD47.262-264 
The targeted deletion of Nhlh2 yields a unique mouse model for inducing obesity, not by 
increasing food consumption or lowering basic metabolic rate compared to wild type animals but 
by reducing overall physical activity levels.247,254 Thus, reduced physical activity in N2KO 
animals plays a crucial role in induction of weight gain and fat accumulation. Consistent with 
previous publications,205,247,253 we observed no difference in food intake between all treatment 
groups during the entire experimental period, while N2KO mice reduced voluntary activity and 
increased body weight gain compared to wild type animals.  
Although not significant, we observed CLA treatment marginally contributed to glucose 
intolerance. It has been suggested that increased fatty acid β-oxidation by CLA might result in 
glucose intolerance, as proposed “the glucose-fatty acid cycle”.265 In fact, it is known that 
increased AMPK activity induces acetyl-CoA carboxylase inactivation, and subsequently results 
in decreasing accumulation of malonyl-CoA, which in turn leads to increased fatty acid β-
oxidation in mitochondria through the induction of upregulated CPT-1 expression.266,267 Enhanced 
fatty acid β-oxidation results in citrate accumulation in the cytosol, which causes inhibition of 
glucose transporter 4 and 6-phosphofructo-1-kinase.268 In fact, it has been previously shown that 
CLA increased CPT-1 expression and activities.17,18,63 Moreover, relatively long-term animal and 
human studies all support that glucose intolerance associated with CLA is an initial response to 
CLA supplementation, however, there have been no reports of adverse effects of CLA on glucose 
homeostasis in long-term human studies longer than 6 months.99,100,107,127  
 Along with glucose intolerance, we observed enlarged liver due to CLA treatment in the 
current study, which is consistent with other animal studies.17,18,63 It has been suggested that 
increased liver weight by CLA may be due to tremendous effects of CLA on fat mobilization 
from adipose tissue and increased hepatic lipogenesis, however, no human studies reported any 
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changes in markers of liver functions associated with CLA supplementation. Thus, this may be a 
species-specific response to CLA.13,269-271 
 In conclusion, we demonstrated that CLA treatment prevents body weight gain and fat 
accumulation by increased physical activity in genetically obese N2KO mice. CLA 
supplementation improved voluntary movement and increased skeletal muscle mass, implying 
enhanced muscle metabolism through stimulating mitochondrial biogenesis signaling. Although 
the precise mechanism underlying the stimulation of mitochondria-related molecular markers is 
not clearly elucidated, it is suggested that CLA exerts its action via the activation of PGC-1α 
through AMPKα phosphorylation, resulting in mitochondriogenic process through regulating 
PGC-1α-PPARδ and/or -Tfam signaling cascades in skeletal muscle. This study provides novel 
insights into the preventive effects of CLA on adult-onset inactivity induced obesity by 
stimulation of muscle metabolism. 
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CHAPTER 6 
EFFECTS OF POST-WEANING ADMINISTRATION OF CONJUGATED 
LINOLEIC ACID (CLA) ON DEVELOPMENT OF OBESITY IN NESCIENT 
HELIX-LOOP-HELIX 2 KNOCKOUT MICE 
 
6.1 Introduction 
Since 1980, the prevalence of childhood obesity has almost tripled.272,273 Along with 
overnutrition, lack of physical activity during childhood period is one of the significant 
contributing factors to development of childhood obesity. Similar to adult obesity, childhood 
obesity is known to be associated with the increased risk of chronic metabolism diseases.274,275 
Even though early childhood has been considered to be critical for health later in life, most 
studies in humans and animals mainly addressed the effects of dietary and exercise regimens 
rather than focusing on early-onset interventions during critical developmental periods.276 
Conjugated linoleic acid (CLA) is a term describing a mixture of 18-carbon unsaturated 
fatty acid isomers with conjugated double bonds. The name, CLA, was first used when its 
anticancer activities were reported in 1987.277 Since then, other biological activities of CLA have 
been reported, including its effects on prevention of atherosclerosis development, modulation of 
immune responses, promotion of young animal growth, and modulation of body composition, 
particularly reduction of body fat and improvement of lean and bone masses.14 It has been 
suggested that CLA reduces body fat by multiple biochemical mechanisms, including increased 
energy expenditure, modulated adipogenesis, and/or enhanced fatty acid β-oxidation.14,15 
The beneficial effects of CLA supplementation during the obesity onset period in nescient 
basic helix-loop-helix 2 (Nhlh2) knock-out mice (N2KO) have been previously reported.205 
Targeted deletion of the Nhlh2 transcription factor expressed in the hypothalamus precedes adult-
onset obesity in mice, resulting from a disruption of the hypothalamic-pituitary axis. While 
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N2KO mice have normal levels of food intake, their spontaneous voluntary movement is 
decreased by more than 50% in both genders.247 It was suggested that CLA supplementation in 
young N2KO animals prevented excessive weight gain by improving voluntary activity.205 
However, it is not clear if supplementation of CLA during pre-obesity stage would benefit later in 
life as it was reported in non-obese animals.31 Thus the purpose of this study was to determine the 
effects of CLA supplementation during the early growth period in N2KO animals on 
development of obesity and symptoms of type 2 diabetes later in life.  
 
6.2 Materials and Methods 
6.2.1 Materials 
CLA was provided by the Natural Lipids Ltd. AS (Hovdebygda, Norway). The CLA 
used consisted of 80.7% CLA (37.8% cis-9,trans-11, 37.6% trans-10,cis-12 and 5.3% other CLA 
isomers) and 13.7% oleic acid, 3.2% stearic acid, 0.4% palmitic acid, 0.2% linoleic acid and 1.8% 
unknown. Semi-purified powdered diet (TD07518) was obtained from Harlan Laboratories 
(Madison, WI). Serum triacylglyceride (TG), glucose, and total cholesterol assay kits were 
purchased from Genzyme Diagnostics (Charlottetown, PE, Canada). DC protein assay kit (Bio-
Rad, Hercules, CA) was used for protein quantitation. Rabbit antibodies for phosphorylated 
AMP-activated protein kinase α (p-AMPKα), AMPKα, phosphorylated phosphatase and tensin 
homolog (p-PTEN), phosphorylated phosphoinositide-dependent kinase (p-PDK), phosphorylated 
protein kinase B at threonine 308 (p-Akt Thr308) and serine 473 (p-Akt Ser473), Akt and 
superoxide dismutase 2 (SOD2) were obtained from Cell Signaling (Berberly, MA). Rabbit 
antibodies for peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), sirtuin 1 
(SIRT1), peroxisome proliferator-activated receptor-δ (PPARδ), nuclear respiratory factor 1 
(NRF-1), mitochondrial transcription factor A (Tfam), cytochrome c (Cyt C), cytochrome c 
oxidase (COX IV), insulin receptor substrate 1 (IRS-1), glucose transporter type 4 (GLUT4) and 
β-actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish 
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peroxidase-conjugated goat anti-rabbit IgG antibody was from Boston Bioproducts Inc. (Ashland, 
MA). Other chemicals used were purchased from either Sigma Chemical Co. (St. Louis, MO) or 
Fisher Scientific (Pittsburg, PA).  
 
6.2.2 Animals and Diets 
All animal work was conducted in compliance with the Institutional Animal Care and Use 
Committee at the University of Massachusetts. As described in a previous report,247 129Sv/J male 
offspring mice were obtained through inbreeding between heterozygous male and female 
breeders. Litters were housed together with dams until weaning. At 3-week-old, all male mice 
were biopsied (0.5-cm tail) for genotyping. Ten wild type and eight male N2KO mice were 
selected for this study, and then placed in individual wire-bottomed cages on a 12:12 h light:dark 
cycle in a temperature and humidity controlled room. During a 1-week acclimatization period, all 
mice were fed a semi-purified powdered control diet (20 w/w% fat) to induce obesity in rodents 
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 and were subjected to baseline test for voluntary movement and glucose tolerance in 
serum. Based on body weight, all animals in different genotype groups (wild type and N2KO) 
were divided into two diet groups and fed either control or 0.5% CLA containing diet for 4 
weeks. Then, all animals received the control diet for 8 weeks. Previously it was determined that 
feeding CLA for 4 weeks in mice was enough to result in changes of body composition as well as 
changes in activity levels.17,30 Moreover, it was reported that most CLA remaining in the tissues 
(liver, adipose tissue and muscle) returned to comparable levels to control animals at 8 weeks 
post withdrawal.30 Thus we selected 8 weeks post CLA supplementation in the current study. 
Dose of CLA was determined based on previous reports that supplementing 0.5% CLA for 2-4 
weeks in rats led to serum level range of 23 to 120 µM and serum levels of CLA after 
supplementation of 0.8-3.2 g per day for 2 months in humans ranged from 23 to 200 µM.27,226  
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The compositions of diets are shown in Table 6.1. Diet and water were available ad libitum 
throughout the experiment and provided freshly twice per week. Body weight and food intake 
were monitored weekly. At the end of the study, mice were fasted for 6 h and sacrificed by CO2 
asphyxiation. Blood was immediately collected by cardiac puncture, and internal organs (liver, 
heart, kidney, spleen, white adipose tissues including epididymal, retroperitoneal and mesenteric 
fat pads) were weighed at sacrifice.  
Table 6.1. Composition of experimental diet for control and conjugated linoleic acid (CLA) groups. 
Ingredient g/kg 
Casein, ‘vitamin-free’ tested 169.1 
L-Cystine   2.2 
Sucrose 100 
Cornstarch 288.5 
Maltodextrin 132 
Cellulose  50 
Soybean oil 195 
CLA or Soybean oil   5 
Mineral mix, AIN-93M-MX (TD 94049)  42.8 
Vitamin mix, AIN-93-VX (TD 94047)   12.4 
Choline bitartrate   3 
tert-Butylhydroquinone   0.04 
Total 1,000 
 
6.2.3 Voluntary movement measurement (Non-exercise physical activity test) 
Non-exercise physical activity (voluntary movement) was recorded using LoliTrack 
Quatro Video Tracking Software Version 1.0 (Loligo Systems, Tjele, Denmark) with a high-
resolution camera under dark condition. This tracking system simultaneously monitored four 
mice placed in individual cages (30 × 46 × 40 cm) during the dark phase (5:00pm-5:00am) once a 
month with free access to diet and water (provided as HydroGel, Clear H2O, Portland, ME). 
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Movement data for 8 h (7:00pm-3:00am) excluding for the first 2 h (5:00pm-7:00pm) during 
early phase for adapting to environmental change and 2 h (3:00am-5:00am) during late phase due 
to lack of movement were analyzed. 
 
6.2.4 Serum Parameters 
The levels of glucose, total cholesterol and TG in serum separated by centrifugation at 
3,000 g for 20 min at 4°C were determined using commercial kits as specified by the 
manufacturer’s instruction. 
 
6.2.5 Glucose Tolerance Test 
As described previously 252, intraperitoneal glucose tolerance tests (IGTT) were 
conducted every four weeks. All mice underwent 6 h fasting and then were subjected to baseline 
measurement of blood glucose levels at 0 min. Blood was collected from the tail vein using blood 
glucose meter, Advocate Redi-Code+ (Advocate Meters Inc., Dorado, Puerto rico). Subsequently, 
30% glucose solution (2.0g glucose/kg body weight) was administered through intraperitoneal 
injection and then blood glucose levels were monitored at 15, 30, 60, 90 and 120 min. Collected 
data were calculated as the areas under the curve (AUC) with SigmaPlot 11.0 (Systat Software, 
Inc., San Jose, CA).  
 
6.2.6 Western Blot Analysis 
The frozen gastrocnemius skeletal muscle tissue was ground and 50 mg aliquots were 
prepared and stored at -80°C until analysis. Each sample was homogenized in premixed lysis 
radioimmune precipitation assay (RIPA) (50 mM Tris-HCl, 10 mM NaCl, 5 mM MgCl2, and 
0.5% NP-40, pH 8.0) buffer (Boston Bioproducts Inc., Ashland, MA), protease inhibitor cocktail 
(Sigma Aldrich, St. Louis, MO) and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, 
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IL) and then lysed on ice for 2 h, and centrifuged at 12,000g for 20 min at 4°C. The concentration 
of protein from tissue lysate was determined using the DC protein assay kit. The normalized 
lysates (37.5 µg/ml protein) were separated by an 8-15% (w/v) sodium dodecyl sulfate-
polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, 
MA). After incubating with appropriate primary rabbit antibodies, membranes were treated with 
horseradish peroxidase-conjugated goat anti-rabbit IgG antibody for 1 h at room temperature. 
Detection was performed using the Enhanced Chemiluminescence solution (Bio-Rad, Hercules, 
CA) with an Image Station 4000MM (Carestream Health, New Heaven, CT). The band density 
was normalized by β-actin intensity as an internal control. The results were quantified using 
Image J software (U.S. National Institutes of Health). 
 
6.2.7 Statistical analyses 
All data analyses were performed by two-way analysis of variance (ANOVA) followed 
by PROC MIXED procedure with Least Square (LS) Means statement of the SAS software 
(Version 9.3, SAS Institute Inc., Cary, NC, USA). For data on body weight, food intake, 
voluntary movement and glucose tolerance test, two-way repeated measures ANOVA and the 
slice option in the LS means statement to examine the group differences at each time point with 
PROC MIXED were used. For internal organ, adipose tissue weight and serum parameters data, 
two-way ANOVA with PROC MIXED were conducted. The experimental groups were compared 
by the multiple comparisons basically Tukey-Kramer’ method in SAS. Dunnett’s test in SAS was 
used for the relative protein expression level. Data are shown as the mean ± S.E. P values less 
than 0.05 are reported as statistically significant. 
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6.3 Results 
6.3.1 Body Weights and Food Intake 
There was significant genotype effect on weight gain; N2KO mice significantly had 
greater body weight gain over wild type mice (P = 0.0001, Fig. 6.1A). CLA supplementation 
during first 4 weeks resulted in no significant different effects on weight gain overall, although 
wild type CLA-fed group had the least body weight gain among all treatment groups during the 
whole experimental period (Fig. 6.1A).  
 
    
Figure 6.1 Effect of post-weaning administration of conjugated linoleic acid (CLA) on body 
weight (A) and food intake (B) in wild type and N2KO mice. 
 
Overall N2KO mice consumed more food than wild type animals during the 
experimental period (P = 0.0252). No significant differences in food intake were observed 
between controls and CLA treatment during pre-obese period, although N2KO CLA group 
temporarily consumed more food right after withdrawal of CLA supplementation for 2 weeks 
(N2KO control; 50.5 ± 5.6 g vs N2KO CLA; 63.0 ± 2.3 g, the mean ± S.E.). Although three-way 
interaction among genotype, CLA and time was observed, there was no significant two-way 
interaction in food intake (Fig. 6.1B). 
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6.3.2 Tissue and Organ Weights 
Total adipose tissue weight including epididymal, mesenteric, and retroperitoneal 
adipose tissue and internal organ weights (liver, heart, kidney and spleen) are shown in Table 6.2. 
Epididymal, mesenteric and total adipose tissue weights were significantly increased in N2KO 
animals compared to wild-types (all P values were less than 0.05), but no significant effects of 
genotypes was observed for retroperitoneal fat weights. No significant effects of CLA 
supplementation for first 4 weeks were observed for adipose tissue weights. 
No differences of genotype effects were observed in the liver, heart and spleen weights, 
while significant genotype effects were observed for the kidney weights (P = 0.0261). CLA-fed 
animals had significantly increased liver, heart and kidney weights compared to control animals. 
No significant interaction between genotypes and CLA was observed in all tissue and organ 
weights. 
 
Table 6.2. Effects of post-weaning administration of conjugated linoleic acid (CLA) on organ 
weights in wild and N2KO mice. 
 
Values represent means ± S.E. (n = 3-5). a-cMeans with different superscripts within the same row are 
significantly different (P < 0.05). P-values in table are from two-way ANOVA. N2KO, nescient helix-loop-
helix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant. 
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6.3.3 Voluntary Movement Measurement (Non-exercise Physical Activity Test) 
To evaluate the effects of post-weaning administration of CLA on physical activity, 
voluntary movement (non-exercise physical activity) was measured every four weeks. Travel 
distance as total (19:00-03:00), and two time periods, early (19:00-23:00) and late (23:00-03:00) 
were shown in Fig. 6.2A-C. The changes of total travel distance over time were shown in Fig. 
6.2D.  
 
Figure 6.2 Effect of post-weaning conjugated linoleic acid (CLA) treatment on voluntary 
movement (non-exercise physical activity) in wild type and N2KO mice. 
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Consistent with the previous reports,205,253 N2KO mice showed significant decreasing 
tendency of activity compared to wild type animals (P = 0.0492). It was evident that all 
experimental groups except wild type CLA group showed declining activity over time (Fig. 
6.2D), with overall CLA effects significant (P = 0.0444), particularly during the late period (P = 
0.0234). No difference in activity between N2KO groups was observed, while CLA fed wild 
types, but not N2KO animals, maintained activity levels throughout experimental. This suggests 
that supplementation of CLA during pre-obese state prevented reduction of voluntary movement 
over time in wild types but not in N2KO animals. 
 
6.3.4 Glucose Tolerance Test 
To determine the effects of post-weaning CLA treatment on glucose homeostasis, 
glucose tolerance tests were conducted every four weeks (Fig. 6.3A-D). N2KO mice showed 
glucose intolerance compared to wild type animals (P = 0.0061). In addition, there was 
significant overall time effect (P = 0.0148), suggesting these animals develop glucose intolerance 
with ageing along with high-fat diet as used in this study. No significant CLA effect was 
observed, however, the CLA treated wild type animals improved glucose tolerance at week 12 
compared to wild-type controls, even after CLA withdrawal for 8 weeks (Fig. 6.3E, P<0.0001 for 
the interaction effect between CLA and time). This suggests that post-weaning CLA 
administration may improve glucose tolerance in wild-types but not in N2KOs. 
 
6.3.5 Serum Parameters 
The serum levels of TG, glucose, and total cholesterol were analyzed and shown in 
Table 6.3. There were no genotype or CLA effect on these markers in this study, except glucose 
levels for CLA (P = 0.036). No interaction between genotype and CLA were observed in all of 
these parameters. 
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Figure 6.3 Effect of time-specific post-weaning conjugated linoleic acid (CLA) treatment on 
glucose levels (A-D), the area under the curve (AUC) change (E) and overall trend of AUC 
change (F) in wild type and N2KO mice. 
 
6.3.6 Effects on Muscle Metabolism 
To assess whether post-weaning administration of CLA attributes to improved skeletal 
muscle energy metabolism, we investigated the AMPK signaling pathway, a master sensor to 
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Table 6.3. Effects of post-weaning administration of conjugated linoleic acid (CLA) on serum 
parameters in wild and N2KO mice. 
 
Values represent means ± S.E. (n = 3-5). P-values in table are from two-way ANOVA. N2KO, nescient 
helix-loop-helix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant. 
 
 
Table 6.3. Serum parameters maintain energy homeostasis (Fig. 6.4). Total AMPKα was 
measured, as it is known that two subunits (α1 and α2) are regulated differentially and overall 
AMPKα activity is more important.279 There were no overall effects of any genotype or CLA 
effects on AMPKα expression, but interaction between them was observed (P = 0.0471) (Fig. 
6.4B). For phosphorylated AMPKα (the active form of AMPKα), N2KO animals had 
significantly lower levels of p-AMPKα compared to wild type (P = 0.0399). The mice 
supplemented CLA for the first 4 weeks showed significantly higher expression of 
phosphorylation of AMPKα over the control groups (Fig. 6.4C, P = 0.0264), particularly wild 
type CLA group compared to the respective control (Fig. 6.4C). In addition, increased ratio of 
phosphorylated AMPKα to AMPKα by CLA was observed (Fig. 6.4D, P = 0.0471). 
Along with AMPKα, SIRT1 (a NAD-dependent deacetylase) is a key activator of PGC-
1α (one major downstream marker for AMPKα). There were no significant effects of genotype 
and CLA on SIRT1 observed, whereas wild type CLA group showed increased SIRT1 expression 
level over N2KO control (Fig. 6.4E). The expression of PGC-1α, a master regulator of 
mitochondrial biogenesis, was not influenced by genotype or CLA either (Fig. 6.4F). However, it 
was evident that CLA treatment had greater effect on PGC-1α than control diet group in wild type 
animals. 
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Figure 6.4 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on protein 
expression of total and phosphorylated AMP-activated protein kinase (AMPK), SIRT1, and PGC-
1α from the gastrocnemius muscle in wild type and N2KO mice. 
 
 
6.3.7 Effects on Mitochondrial Biogenesis-related Factors 
We further determined the effect of post-weaning CLA supplementation on 
mitochondrial biogenesis in the gastrocnemius muscle. Mitochondria are the important organelle 
to determine the oxidative capacity and fatigue resistance, resulting in prolonged endurance 
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capacity.249,280,281 For mitochondrial biogenesis several nuclear encoded precursor proteins are 
involved in this metabolic process10,230,282, among them we selected PPARδ, NRF-1 and Tfam.  
PPARδ is a marker involved in mitochondrial biogenesis as well as muscle type 
transformation from glycolytic to oxidative fiber.192 No significant overall effects of genotypes or 
CLA were observed on PPARδ, however, wild type CLA-fed animals showed significantly 
greater expression levels of effect of PPARδ compared to both control diet groups (Fig. 6.5B). No 
significant difference in NRF-1, a regulator to mediate nuclear-encoding mitochondrial proteins, 
was observed in all experimental groups (Fig. 6.5C). The expression of Tfam, which is the key 
regulator for mitochondrial DNA replication and transcription, was significantly down-regulated 
in N2KO mice over wild type mice (P = 0.0062). The CLA supplemented group in wild type 
animals showed significantly greater Tfam expression over control group in N2KO mice (Fig. 
6.5D). 
 
Figure 6.5 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on mitochondrial 
biogenesis-related factors from the gastrocnemius muscle in wild type and N2KO mice. 
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To estimate overall mitochondrial relative content we used an indirect method to 
measure mitochondrial proteins including cytochrome c and COX IV located in the inner 
membrane of mitochondria.228,232 Additionally, we tested another mitochondrial protein, 
superoxide dismutase 2 (SOD2) in the inner mitochondrial matrix, to assess mitochondrial 
function.234 The expression levels of cytochrome c were significantly decreased in N2KO mice 
compared to wild type animals (P = 0.0496) but no CLA effects were observed (Fig. 6.6B). No 
genotype or CLA effects were observed in COX IV (Fig. 6.6C). Overall SOD2 protein levels 
were significantly reduced in N2KO mice (P = 0.0224), while no effects of CLA were observed 
(Fig. 6.6D). 
 
 
Figure 6.6 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on mitochondrial 
content and function from the gastrocnemius muscle in wild type and N2KO mice. 
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6.3.8 Effects on Markers of Glucose Metabolism 
Along with assessment of post-weaning administration of CLA on mitochondrial biogenesis-
related factors, we determined the effects of CLA supplementation during first 4 weeks on 
markers of glucose metabolism in the gastrocnemius muscle. The expression levels of IRS-1, a 
member of IRS family regulating insulin signaling, were significantly decreased in N2KO 
animals over wild types, while no CLA effects were observed (Fig. 6.7B, overall genotype effect, 
P = 0.0335). 
A downstream biomarker of IRS (PTEN, attributed to negatively regulate the AKT signaling 
pathway) significantly reduced phosphorylation (inactive form of PTEN) in N2KO mice 
compared to wild type animals (P = 0.0094). No significant effect of post-weaning administration 
of CLA was observed on PTEN expression. However, CLA-treated wild type animals 
significantly upregulated phosphorylated PTEN compared to the respective control, while no 
differences were observed in N2KO animals (Fig. 6.7C). 
No difference in protein expression of phosphorylated PDK, a downstream marker of 
PTEN, was observed for both genotype and CLA (Fig. 6.7C). There were no significant effects of 
genotypes and CLA in total AKT expressions and phosphorylated AKT (Serine 473) and GLUT4, 
one of the insulin-regulated glucose transporters (Fig. 6.7D-G). However, we observed 
marginally increased responses from wild type animals fed CLA on phosphorylated AKT 
(Threonine 308) compared to the respective control (P = 0.0547 and P = 0.0528, respectively). 
 
6.4 Discussion 
It was previously reported that supplementation of CLA prevents weight gain and body 
fat accumulation during both the growth period and in aged N2KO mice.57,205,283 Particularly, 
CLA increased voluntary activity when supplemented during growth period.205,283 Results from 
the current study suggest that supplementation of CLA in pre-obese state may reduce weight gain 
in normal animals but not in the genetically induced inactive adult-onset animal model, although  
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Figure 6.7 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on glucose 
metabolism from the gastrocnemius muscle in wild type and N2KO mice. 
 
the stimulation of voluntary activity and improved glucose tolerance remain even after CLA 
withdrawal in this model. 
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Previously CLA was reported to be linked with reduced food intake in a number of 
animal models, although it was not consistent.28-30,71 Moreover, it was determined that the 
reduction of food intake by CLA was independent of its effects on body fat reduction.28,30 Others 
suggested that CLA reduces food intake by decreasing neuropeptides Y (NPY) and agouti-related 
protein (AgRP), both of which are known to be related to increased appetite 284 and inducing the 
storage of glycogen in muscle and liver, which may subsequently serve as satiety signals.285,286 In 
the current study, we did not observe any significant differences in food intake during CLA 
supplementation periods in both genotypes. However, when CLA was withdrawn, apparent 
compensation of food intake occurred in N2KO animals fed CLA, but not in wild type animals, 
coincided with greater weight gain during this period (Week 4-6 in Fig. 6.1A). It is not clear how 
CLA influenced food intake in these animals, however, these results suggest that CLA may 
influence food intake differently in obese animals, which has been previously reported in other 
animal models.28,30,32,71  
 We observed that N2KO mice had significantly reduced physical activity consistent with 
previous reports for N2KO animals.205,247,248 Overall, post-weaning CLA supplementation 
significantly prevented reduction of voluntary activity levels compared to controls, particularly in 
wild type animals. Intriguingly, our results showed that the effects of CLA on activity during the 
late phase (23:00-03:00) might remain even after termination of CLA treatment up to 8 weeks, 
whereas during the early phase (19:00-23:00) there was no significant CLA effect in all 
experimental groups.  
 Among various molecular mechanisms to affect increased or maintained physical 
activity levels, AMPK signaling pathway has drawn significant attention since the 1990s.183 
Upregulated AMPK signaling pathway is involved in skeletal muscle energy metabolism as well 
as mitochondrial biogenesis, resulting in enhanced endurance capacity and attenuated exercise 
intolerance.3-5,287 Previously, our group demonstrated the effect of CLA on stimulation of 
mitochondrial biogenesis through AMPK signaling pathway.250 In the same context, our data 
81 
supported post-weaning administration of CLA might stimulate activation of AMPKα and related 
factors in wild type but not in N2KO animals.  
 Wild type animals fed CLA for first 4 weeks showed improved glucose tolerance over 
time even after no benefits on weight were observed compared to respective control, suggesting 
CLA may have lasting effects on glucose metabolism later in life. Based on this observation, we 
assessed effects of CLA treatment during growth period on glucose metabolism through insulin 
signaling pathway. Among several measured markers involved in insulin signaling cascades, 
phosphorylated PTEN and phosphorylated AKT at threonine 308 partially provided evidence 
regarding how to moderate glucose tolerance in the current study. PTEN and AKT are important 
effectors of insulin responses mediating glucose uptake and glycogen synthesis in skeletal 
muscle.288-291 Our data are consistent with early studies that CLA specific isomers mediate AKT 
sensitization.194,196 
 Current the results suggest potential benefits of post-weaning CLA administration to 
reduce health risk, as suggested previously.253,283 This is important since one potential health 
concern associated with CLA supplementation is glucose intolerance. We observed a non-
significant increase in glucose intolerance following CLA supplementation in wild type mice 
(Fig. 6.3B, week 4), however, when CLA was withdrawn, glucose tolerance improved in the 
treated groups (week 12 in Fig. 6.3D). As suggested before, this may be due in part to significant 
shift of energy metabolism by CLA, such as increased fatty acid β-oxidation associated with 
reduced glucose utilization.265,268 However, further studies such as HOMA-IR to better understand 
glucose and insulin metabolism are needed to determine how post-weaning administration of 
CLA changes energy sources. 
As seen in previous studies,17,18,152 we observed a significant increase in liver weight, as 
fatty liver, after CLA supplementation. It is unlikely that CLA is directly accumulated in the liver 
as levels of CLA in the liver and muscle reached maximum 1 week for liver and 2 weeks for 
muscle after supplementation in mice.292 Previously it was reported that CLA fed animals 
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accumulate TG in the liver.293,294 It is believed to be associated with CLA’s dramatic effects on 
lipid metabolism, particularly in the liver and adipose tissues, increased hepatic lipogenesis and 
decreased fat accumulation in adipose tissues.13,15,270,271 It is unlikely that enlarged liver caused by 
CLA is due to increased glycogen content as it was previously shown that CLA had no effects on 
enzyme activities involved in gluconeogenesis.292 In addition, previous studies reported no 
pathologically significant observations after 18 months CLA supplementation or no changes in 
hepatic gene expressions in lipogenesis from N2KO animals.57,205,295 Although we provided CLA 
during pre-obese state only and then withdrew CLA, the significant effect of CLA on liver weight 
still remains. This is consistent with the previous study that withdrawal of CLA did not 
completely reverse liver enlargement at the end of a 4 week recovery period.269 Our study might 
not have enough adaptive time to complete this reversal of CLA’s effect. Thus, additional 
investigation of relationship between short-term CLA supplementation and changes in hepatic 
genes should be considered to determine if the liver enlargement caused by CLA is completely 
reversible or not. Clinical trials with CLA reported no changes or increased markers for liver 
function, and all were within the normal ranges. In addition, it was reported that a high-dose of 
CLA (14.6 g cis-9,trans-11 and 4.7g trans-10,cis-12 CLA per day) for 3 weeks had no changes 
on markers of liver function in healthy subjects. Thus, it is possible that rodents are more 
sensitive to CLA’s effect compared than humans. 
In conclusion, CLA supplementation during pre-obese state may attenuate reduction of voluntary 
activity and glucose intolerance after CLA withdrawal in this mouse model. However, it is not 
sufficient per se to maintain health benefits like prevention of weight gain and fat accumulation 
until later life in genetically obese mice. Wild type animals fed CLA may activate AMPKα and 
PPARδ as well as promote desensitization of PTEN and sensitization of AKT at threonine 308 in 
gastrocnemius skeletal muscle, improving voluntary activity and glucose homeostasis. We 
suggest that post-weaning administration of CLA may partially stimulate the underlying 
molecular targets involved in muscle energy metabolism in normal animals but not in the 
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genetically induced inactive adult-onset animal model. The present study would provide a 
scientific foundation for future trials of targeted application of post-weaning CLA intervention in 
modulating long-term obesity. If further research on genetically predisposed obese mice 
discovered an appropriate intervention or combination with an addition regime like exercise, it 
may be possible to more effectively be used to prevent childhood obesity. 
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CHAPTER 7 
CONJUGATED LINOLEIC ACID (CLA) PROMOTES ENDURANCE 
CAPACITY VIA PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 
(PPAR) δ-MEDIATED METABOLISM IN MICE 
 
7.1 Introduction 
There are two distinct types of exercise training: strength and endurance. Strength 
exercises such as weightlifting and bodybuilding promote protein synthesis and then induce 
hypertrophy of muscle cells. On the other hand, endurance exercises including jogging, 
swimming and cycling stimulate mitochondrial biogenesis and then contribute to decreased 
incidences of obesity through enhanced energy expenditure and switching the energy source from 
glucose to fat 296. Also, chronic endurance training triggers a remodeling of the skeletal muscle 
fiber phenotype from type II (glycolytic fast-twitch fibers) to type I (oxidative slow-twitch 
fibers). In general, type I fibers in skeletal muscle have a greater density of mitochondria than 
type II fibers. Thus, oxidative type I fibers promotes fatty acid β-oxidation to spend the stored fat 
in the body 297. As a consequence, it induces body fat reduction, leading to the prevention of 
obesity. 
It is known that mitochondrial biogenesis and a shift of fiber type composition are major 
metabolic events that influence endurance exercise training, and vice versa 296. The primary 
biomarkers implicated in mitochondrial biogenesis and fiber type transformation in skeletal 
muscle are peroxisome proliferator-activated receptor δ (PPARδ) and PPARγ coactivator 1α 
(PGC-1α) 257. Although it is well established that PGC-1α acts as a master regulator in 
mitochondrial biogenesis, mice that ectopically overexpressed PGC-1α showed a remarkable 
conversion of muscle fiber type II to type I. Likewise, muscle specific overexpression of PPARδ 
in mice simultaneously increased the number of copies of mitochondrial DNA and up-regulated 
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the expression levels of mitochondrial biogenesis-related genes, inducing a shift of skeletal 
muscle fibers from type II to type I 192.  
During the last two decades conjugated linoleic acid (CLA) has gained significant attention 
as a bioactive compound to prevent obesity. Although most of CLA’s anti-obesity effects have 
been focused on body fat reduction, accumulated evidence demonstrated that CLA increased lean 
body mass and enhanced physical performances 14,120. In fact, the previous studies in rodents 
reported that CLA improved voluntary activity and endurance capacity through the modulation of 
molecular targets such as carnitine palmitoyltransferase 1 (CPT1), uncoupling protein 2 (UCP2) 
and peroxisome proliferator-activated receptor δ (PPARδ) in skeletal muscle 17,18. Recently, it was 
revealed that the specific CLA isomers, cis-9,trans-11 and trans-10,cis-12, induced the up-
regulation of key molecular markers involved in mitochondrial biogenesis 250. This evidence 
provides the opportunity for future studies to investigate the effects of CLA on skeletal muscle 
metabolism. Thus, we investigated the regulating mechanisms of CLA in skeletal muscle to elicit 
the effects of CLA on endurance capacity in mice, and to clarify the interaction of CLA and 
exercise based on PPARδ-mediated metabolism. 
 
7.2 Materials and methods 
7.2.1 Materials 
CLA was provided by Natural Lipids Ltd. AS (Hovdebygda, Norway). The purity of 
CLA was 80.7% (37.8% cis-9,trans-11, 37.6% trans-10,cis-12 and 5.3% other CLA isomers and 
the remainder of the preparation was 13.7% oleic acid, 3.2% stearic acid, 0.4% palmitic acid, 
0.2% linoleic acid and 1.8% was unknown). Semi-purified powdered diets (TD07518, 95% basal 
mix) were obtained from Harlan Laboratories (Madison, WI). Serum triacylglyceride (TG), 
glucose, and total cholesterol assay kits were purchased from Genzyme Diagnostics 
(Charlottetown, PE, Canada). Serum non-esterified fatty acids (NEFA) and L-Lactate were 
obtained from BioAssay Systems (Hayward, CA). The blood urine nitrogen (BUN) assay kit was 
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purchased from BioQuant (San Diege, CA). DC protein assay kits for analysis of protein 
concentration were from Bio-Rad (Hercules, CA). Rabbit antibodies for phosphorylated AMP-
activated protein kinase α (p-AMPKα), AMPKα, phosphorylated phosphatase and superoxide 
dismutase 2 (SOD2) were obtained from Cell Signaling (Berberly, MA). Rabbit antibodies for 
PGC-1α, sirtuin 1 (SIRT1), PPAR, nuclear respiratory factor 1 (NRF-1), mitochondrial 
transcription factor A (Tfam), cytochrome c (Cyt C) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). Horseradish peroxidase-conjugated goat anti-rabbit IgG antibody was from Boston 
Bioproducts Inc. (Ashland, MA). Other chemicals used were purchased from either Sigma 
Chemical Co. (St. Louis, MO) or Fisher Scientific (Pittsburg, PA). 
 
7.2.2 Animals and diet 
All work related to animals was done in compliance with the Institutional Animal Care 
and Use Committee at the University of Massachusetts, Amherst. Twenty 10-week-old male 
129Sv/J mice were obtained from breeding colonies. All mice were placed in individual wire-
bottom cages with 12h light and dark cycles in a temperature and humidity-controlled room. All 
mice underwent a 1-week acclimatization period. During that period, a control powder diet with 
40% calories from fat was provided to all mice. They were subjected to baseline testing for 
endurance capacity and voluntary activity. All mice were divided into four different groups 
according to diet and exercise regimes, either as control or 0.5% CLA with high-fat (40% fat 
calorie) diets, as well as sedentary or exercise groups. The dose of CLA used for the current study 
was determined on the basis of previous reports in rats and humans. In rats, 0.5% CLA 
supplementation for 2−4 weeks caused a range between 23−120 µM in serum and 0.8−3.2 g per 
day supplemented with CLA for 2 months in humans led to serum levels from 23 to 200 µM 27,226. 
The formulation of diets was shown in Table 7.1. The duration of this study was four weeks. 
Body weight and food intake were recorded once a week. After a four-week intervention, the 
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mice fasted for 4 h, exercised for 15 min, run the same way as the training protocol, and then 
sacrificed by CO2 asphyxiation. For analysis of serum markers, blood was collected using the 
cardiac puncture method. Three different parts of adipose tissue (epididymal, retroperitoneal and 
mesenteric), two designated parts of skeletal muscle (gastrocnemius and quadriceps) and other 
organs (liver, heart, kidney and spleen) were harvested and weighed. 
 
Table 7.1. Composition of experimental diet for control and conjugated linoleic acid (CLA) groups. 
Ingredient g/kg 
Casein, ‘vitamin-free’ tested 169.1 
L-Cystine   2.2 
Sucrose 100 
Cornstarch 288.5 
Maltodextrin 132 
Cellulose  50 
Soybean oil 195 
CLA or Soybean oil   5 
Mineral mix, AIN-93M-MX (TD 94049)  42.8 
Vitamin mix, AIN-93-VX (TD 94047)   12.4 
Choline bitartrate   3 
tert-Butylhydroquinone   0.04 
Total 1,000 
 
7.2.3 Endurance capacity test 
All mice were subjected to running training on the treadmill (Columbus Instrument, 
Columbus, OH) during the acclimatization period (week 0). The protocol of adaptation placed all 
mice on the treadmill to run for 15 min with a speed of 10 m/min on a 0° incline under the control 
of an electric shock grid. This training for adaptation was repeated three times and then all mice 
were measured on a baseline of endurance capacity, for a total running time (min) and distance 
(m) at the end of the adaptation period.  
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During the whole experimental period, mice in the exercise groups trained with running 
exercises five times a week on the motorized treadmill. The detailed endurance training protocol 
performed running training for a total of 15 min (10 m/min for the first 10 min, then an increase 
of 1 m/min every minute for the following 5 min, with a final speed of 15 m/min for training) on 
a 10° inclination with an electric shock grid (0.97 mA) to encourage continuous running.  
Endurance capacity was evaluated biweekly. The testing protocol used the same initial 
conditions as the training protocol (10 m/min on 10° inclination), however, the speed was 
increased by 1 m/min every minute until reaching 25 m/min, and the speed of 25 m/min was 
maintained until they were fatigued or exhausted. Exhausted means mice stay on the electric 
shock grid for five continuous seconds or for three times over two seconds 298,299. The total 
running time and distance determined that these variables were representative markers to reflect 
endurance capacity. 
 
7.2.4 Voluntary movement measurement (Non-exercise physical activity test) 
Voluntary movement was recorded using LoliTrack Quatro Video Tracking Software 
Version 1.0 (Loligo Systems, Tjele, Denmark) with a high-resolution infrared camera during the  
dark cycle (5:00pm-5:00am) every other week. Animals were individually placed into cages with 
free access to diet and water (provided as HydroGel, Clear H2O, Portland, ME). The cage (30 × 
46 × 40 cm) used for activity monitoring was larger than the typical cage to avoid limited 
voluntary movements. Among the monitored movement data for 12 h (5:00pm-5:00am), and 8 h 
(7:00pm-3:00am) were analyzed with the exception of the first 2 h (5:00pm-7:00pm) and 2 h 
(3:00am-5:00am) due to early adaption and a lack of movement, respectively. 
 
7.2.5 Serum parameters 
The levels of glucose, total cholesterol, TG, NEFA, BUN and L-Lactate in serum were 
separated by centrifugation at 3,000 g for 20 min at 4°C and were subsequently measured using  
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commercial kits. 
 
7.2.6 Western blot analysis 
Each sample from gastrocnemius muscle tissue was homogenized in radioimmune 
precipitation assay (RIPA) (50 mM Tris-HCl, 10 mM NaCl, 5 mM MgCl2, and 0.5% NP-40, pH 
8.0) buffer (Boston Bioproducts Inc., Ashland, MA), protease inhibitor cocktail (Sigma Aldrich, 
St. Louis, MO) and a phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL) and was 
lysed on ice for 2 h with gentle shaking, then centrifuged at 14,000g for 20 min at 4°C. The 
protein concentration in tissue lysate was normalized at 50 µg/ml of protein. The normalized 
samples were mixed with loading buffer, and then separated by a 10-15% (w/v) sodium dodecyl 
sulfate-polyacrylamide gel and were transferred onto a polyvinylidene fluoride membrane 
(Millipore, Bedford, MA). After blocking, proteins were probed with primary rabbit antibodies, 
and were then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody 
for 1 h at room temperature. For detection, the Enhanced Chemiluminescence solution (Bio-Rad, 
Hercules, CA) was used and developed under the Image Station 4000MM (Carestream Health, 
New Heaven, CT) setting. GAPDH was used as a loading control for normalization. The results 
were quantified using Image J software (U.S. National Institutes of Health). 
 
7.2.7 mRNA analysis  
 Total RNA was isolated from the gastrocnemius muscle tissue (50 mg) in TRIzol 
reagent (Invitrogen, Calsbad, CA), and was then reversely transcribed to cDNA using a High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Forster, CA). cDNA with 
predesigned TaqMan gene expression assay kits was used for the relative quantitation. The target 
genes were lipoprotein lipase (LPL, Mm00434764_m1), fatty acid binding protein 4 (Fabp4, 
Mm00445878_m1), PPARα (Mm00440903_m1), CPT1β (Mm00487200_m1) and UCP2 
(Mm00627597_m1) for lipid metabolism, and phosphoinositide 3-kinase (PI3K) 
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(Mm00803160_m1), pyruvate dehydrogenase kinase, isoform 4 (PDK4, Mm01166879_m1), 
protein kinase B1 (AKT1, Mm01331626_m1) and glucose transporter type 4 (GLUT4, 
Mm01245502_m1) for glucose metabolism. For analysis of muscle fiber type transformation we 
used four target genes, myosin heavy chain 1 (MHC1, Mm01332493_m1), MHC2 
(Mm01332564_m1), MHC3 (Mm01332463_m1) and MHC7 (Mm01332518_m1). GAPDH 
(Mm99999915_g1) and 18S ribosomal RNA (18S rRNA, Mm03928990_g1) were used for 
internal standards. All reactions were triplicated with the StepOnePlus Real-Time PCR System 
(Applied Biosystems, Foster, CA). The program of reaction was 2 min at 50°C and 10 min at 
95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were calculated using 2–∆∆Ct. 
 
7.2.8 Statistical analyses 
Data were analyzed by two-way analysis of variance (ANOVA) followed by PROC 
MIXED with Least Square (LS) Means options of the SAS software (Version 9.3, SAS Institute 
Inc., Cary, NC, USA). For data on body weight, food intake, endurance capacity and voluntary 
movement, two-way repeated measure ANOVA and the slice option in the LS means statement 
were used to examine the group differences at each time point with PROC MIXED. For internal 
organs, adipose and skeletal muscle tissue weight, serum parameters, the relative protein and 
mRNA expression level data, two-way ANOVA with PROC MIXED was used. The Tukey-
Kramer’s method in SAS was used for the multiple comparisons among the experimental groups. 
Data were shown as the mean ± S.E. P values less than 0.05 are reported as statistically 
significant. 
 
7.3 Results 
7.3.1 Body weights and food intake 
CLA fed mice gained less body weight than control diet groups from week 2, and 
maintained this trend throughout the experiment (overall CLA effect, P < 0.0001). Along with 
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CLA effects, exercise effects on body weight gain in trained mice were significant (overall 
exercise effect, P = 0.0218). No interaction was observed for diets and exercise in body weight 
gain (Fig. 7.1A). At week 2, mice supplemented with CLA decreased food intake compared to 
control diet groups. However, there was no significant difference in food intake at the end of the 
experiment between any of the groups. Overall CLA and time effects influenced food intake (P = 
0.0187 and P < 0.0001, respectively) and there was a significant interaction between the two (P = 
0.0007). Exercise effect was not observed in food intake (Fig. 7.1B).  
  
Figure 7.1 Effects of conjugated linoleic acid (CLA) on body weight (A) and food intake (B) in 
sedentary and exercise-trained mice. 
 
7.3.2 Tissue weights 
Total and individual adipose tissue (epididymal, retroperitoneal, and mesenteric adipose 
tissue), skeletal muscle (gastrocnemius and quadriceps), liver, heart and spleen weights are shown 
in Table 7.2. Overall CLA-fed mice showed significantly less adipose tissue accumulation than 
control diet groups, while no exercise effect was observed in adipose tissue weights. The tissue 
weights in gastrocnemius muscle were significantly increased by CLA supplementation (P = 
0.0035). Particularly, CLA-fed mice in the exercise trained group had the most gastrocnemius 
muscle mass. No differences of exercise effect were observed in the liver, heart and spleen 
weights, whereas CLA supplementation significantly influenced the liver weight.  
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Table 7.2. Effects of conjugated linoleic acid (CLA) on organ weights in sedentary and exercise-
trained mice. 
 
Values represent means ± S.E. (n = 5). a-bMeans with different superscripts within the same row are 
significantly different (P < 0.05). P-values in table are from two-way ANOVA. CLA, conjugated linoleic 
acid; n.s., not significant. 
 
7.3.3 Endurance capacity and voluntary movement (non-exercise physical activity) 
To evaluate endurance capacity, we determined the maximum running time and distance 
on the motorized treadmill. Animals in the CLA groups significantly improved the maximum 
running time and distance over mice in the control diet groups (P = 0.0166 and P = 0.0174, 
respectively). Exercise effect failed to reach significant values in endurance capacity. Time effect 
influenced running time and distance. On the other hand, no interaction among time, diets and 
exercise were observed. The CLA supplementation and exercise-combined group significantly 
prolonged the maximum running time (2.4-fold) and distance (3.2-fold) in comparison to the 
sedentary control diet group at week 4. Furthermore, CLA-fed mice in the sedentary group also 
increased their running time (1.6-fold) and distance (1.9-fold) compared to the sedentary control 
diet group at the same time point (Fig. 7.2A and 7.2B). All experimental groups except the 
sedentary control group steadily increased the maximum running distance over time (Fig. 7.2C). 
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Effects of CLA on non-exercised physical activity were determined by measuring 
voluntary movement three times including a baseline test during the entire experimental period 
(Fig. 7.2D). Overall CLA and exercise effects did not show differences in voluntary movement, 
although CLA-fed animals showed an increase in voluntary movement compared to control diet-
fed mice within the sedentary groups at week 4 (paired test, P = 0.0157). On the other hand, in the 
exercise-trained groups, CLA supplementation led to no significant changes in voluntary 
movement in comparison to control diet feeding.  
  
Figure 7.2 Effects of conjugated linoleic acid (CLA) on maximum running time (A), distance (B) 
and trend (C), and voluntary movement (D) in sedentary and exercise-trained mice. 
 
7.3.4 Serum parameters 
The concentrations of serum metabolic parameters are shown in Table 7.3. The CLA 
supplemented animals had significantly lower levels of serum TG than mice in the control diet 
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groups (P = 0.0431). No difference of overall CLA and exercise effects were observed for 
glucose, total cholesterol, NEFA, BUN and L-Lactate in mice.  
 
Table 7.3. Effects of conjugated linoleic acid (CLA) on serum parameters in sedentary and 
exercise-trained mice. 
 
Values represent means ± S.E. (n = 5). P-values in table are from two-way ANOVA. CLA, conjugated 
linoleic acid; n.s., not significant; NEFA, non-esterified fatty acid; BUN, blood urea nitrogen. 
 
 
7.3.5 Effects on biomarkers in skeletal muscle energy metabolism 
To determine the effects of CLA and/or exercise on skeletal muscle metabolism, we 
investigated the AMPK-related molecular biomarkers in the regulatory pathway for PPARδ on 
the basis of the previous study 18,250. There were no significant overall effects of CLA or exercise 
on total AMPKα in all treatments (Fig. 7.3B), while phosphorylated AMPKα (the active form of 
AMPKα) was significantly up-regulated in the exercise trained mice (P = 0.0342 for overall 
exercise effect, Fig. 7.3C). As a consequence, the ratio of phosphorylated AMPKα to AMPKα 
was significantly increased in the exercise trained animals (P = 0.0197 for overall exercise effect, 
Fig. 7.3D). SIRT1, a NAD-dependent deacetylase cross-talking to AMPK, was significantly 
influenced by CLA supplementation (P = 0.0009 for overall CLA effect, Fig. 7.3E). However, 
there was no significant effect of exercise in SIRT1 expression. Similarly, the expression of PGC-
1α showed significant differences in the CLA-fed groups (P = 0.0127 for overall CLA effect), but 
not in the exercise trained mice (Fig. 7.3F). 
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7.3.6 Effects on biomarkers in mitochondrial biogenesis signaling cascades 
 On the basis of the evidence that CLA up-regulated SIRT1 and PGC-1α in the CLA-fed 
mice in Fig. 7.3, we further studied the effects of CLA and/or exercise on mitochondrial  
 
Figure 7.3. Effects of conjugated linoleic acid (CLA) on protein expression of AMP-activated 
protein kinase (AMPK), sirtuin 1 (SIRT1), and peroxisome proliferator-activated receptor γ 
coactivator 1 α (PGC-1α) in sedentary and exercise-trained mice. 
 
biogenesis signaling cascades in the gastrocnemius muscle. It is known that endurance exercise 
training stimulates mitochondrial biogenesis, resulting in improved oxidative capacity and 
reduced muscle fatigue 249. In fact, PGC-1α is a master regulator in mitochondrial biogenesis, 
which orchestrates several nuclear encoded proteins. Among them, we primarily investigated 
three major molecular biomarkers, PPARδ, NRF-1 and Tfam. In addition, the activities of 
mitochondrial proteins, cytochrome c and SOD2, were evaluated for changes of mitochondrial 
function by nutritional and physical treatments. Overall CLA effects showed significantly 
increased expression levels of PPARδ compared to control-fed animals (P = 0.0051 for overall 
CLA effect, Fig. 7.4B), while no exercise effect was observed for PPARδ. The CLA-fed mice 
significantly increased NRF-1 activity, a marker that regulates nuclear-encoding mitochondrial 
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proteins, in comparison to control-fed animals (P = 0.0016 for overall CLA effect). The 
expression levels of Tfam, a major regulator for mitochondrial DNA replication and transcription, 
in the CLA supplemented groups were greater than the controls (P = 0.0195 for overall CLA 
effect). There were no exercise effects in both activities of NRF-1 and Tfam (Fig. 7.4C and 
7.4D).  
 We further determined expression levels of mitochondrial proteins, cytochrome c which 
is located in the inner membrane of mitochondria, and SOD2 which protects mitochondria from 
reactive oxygen species. No significant overall effects of CLA or exercise were observed on 
cytochrome c and SOD2; however, the exercise trained mice showed marginally increased 
expression levels of both proteins, although the results were not significant (Fig. 7.4E and 7.4F). 
 
 
Figure 7.4. Effects of conjugated linoleic acid (CLA) on mitochondrial biogenesis-related 
molecular markers from the gastrocnemius muscle in sedentary and exercise-trained mice. 
 
7.3.7 Effects on muscle fiber type composition 
 The effects of CLA and/or exercise on changes in the composition of the four different 
genes in myosin heavy chain (MYH) were evaluated in the gastrocnemius muscle (Fig. 7.5). 
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These myosin heavy chain genes include MYH7 (slow-twitch fiber type I), MYH3 (embryonic 
fiber), MYH2 (slow/fast-twitch fiber type IIa) and MYH1 (fast-twitch fiber type IIx/d). The 
significant differences in MYH7 (P < 0.0001), MYH3 (P = 0.0019) and MYH1 (P = 0.0041) were 
observed in the CLA-fed animals. On the other hand, the exercise trained mice showed 
significantly increased gene expression levels of MYH2 (P = 0.0205 for overall exercise effect). 
Specifically, the CLA-fed mice in the exercise trained group expressed the most mRNA levels of 
MYH7, MYH3 and MYH2 among all experimental groups.  
 
Figure 7.5. Effects of conjugated linoleic acid (CLA) on skeletal muscle fiber type 
transformation. Samples were obtained from the gastrocnemius muscle in sedentary and exercise-
trained mice. 
 
7.3.8 Effects on lipid and glucose metabolism in skeletal muscle 
 To determine the effects of CLA and/or exercise on lipid metabolism in skeletal muscle, 
the selected genes measured the mRNA levels in the gastrocnemius muscle (Fig. 7.6A). The CLA 
supplementation significantly increased the mRNA expression of LPL (the master regulator of 
fatty acid uptake, P = 0.00154), PPARα (the key regulator of lipid metabolism, P = 0.00154) and 
CPT 1β (the key enzyme of fatty acid β-oxidation, P = 0.039), while no effects of CLA were 
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observed on Fabp4 and UCP2 in muscle. Overall exercise effect was not shown in lipid 
metabolism.  
 
 
Figure 7.6. Effects of conjugated linoleic acid (CLA) on mRNA expressions of selected genes 
representative to lipid metabolism (A) and glucose and insulin metabolism (B) in the 
gastrocnemius muscle in sedentary and exercise-trained mice. 
 
The relative mRNA expression levels of PI3K, PDK4, AKT1 and GLUT4, markers for 
glucose and insulin metabolism, were determined in the gastrocnemius muscle (Fig. 7.6B). 
Among these targets, mRNA levels of GLUT4 (the insulin-regulated glucose transporter) were 
significantly up-regulated by CLA supplementation (P = 0.0447), but not by exercise training. 
 
7.4 Discussion 
 Previously, numerous studies with CLA investigated the mechanisms to reduce body 
weight and body fat mass by modulating metabolism in adipose tissues 15,16. However, the effects 
of CLA on skeletal muscle metabolism have garnered relatively less attention, even though a 
number of early studies demonstrated that CLA increased lean body mass, including muscle mass 
and improved physical activities 120. In the current study, we have assessed the effects of CLA on 
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endurance capacity and the metabolic alteration of intracellular molecular markers in skeletal 
muscle. Of particular importance, up- and down-stream markers of PPARδ regulated 
mitochondrial biogenesis and muscle fiber type composition. Those markers were primarily 
investigated as the metabolic events that influence endurance capacity. Results from the present 
study indicated that CLA supplementation, but not exercise training, stimulated mitochondrial 
biogenesis and induced genes of myosin heavy chains composed of muscle fiber in mice, 
resulting in enhancement of lipid metabolism. Thus, CLA supplementation might be a more 
effective way to control skeletal muscle metabolism rather than exercise training alone. 
 In this study, the CLA-fed mice had an enhanced endurance capacity compared to the 
control diet groups. Furthermore, 0.5% CLA supplementation combined with endurance training 
showed a significant additional effect on the maximum running time and distance (Fig. 7.2). 
These results are consistent with the previous studies that demonstrate increased maximum 
swimming or running capacity in mice by CLA treatment 18,149,202-204. Indeed, three early studies 
reported that 0.5% CLA supplemented mice increased voluntary movement (non-exercise 
physical activity) 17,205,300. Although our results did not observe the overall CLA effect in 
voluntary movement, the CLA-fed mice significantly traveled greater distances compared to 
control-fed animals within the sedentary group. On the other hand, no CLA effect was observed 
in the trained mice. This result is supported by a study where the trans-10,cis-12 CLA isomer 
improved endurance capacity, while there were no changes in voluntary movement in the trained 
mice 18. Ohnuki et al.148 also demonstrated no effect of a single oral administration of CLA on 
locomotive activity. Thus, further studies with CLA are needed to discover the correlation 
between voluntary movement and extensive endurance training. 
 It is known that endurance training activates various signaling cascades in skeletal 
muscle energy metabolism. In particular, AMPK plays a central role in the adaptive response to 
exercise, since AMPK senses lowered ATP levels due to increased energy demands by exercise, 
which in turn leads to the activation of oxidative metabolism for energy homeostasis in the body 
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301
. Our results demonstrated that the exercise trained groups had remarkably upregulated AMPK 
phosphorylation levels in comparison to the sedentary animals, although other markers in the 
down-stream signaling pathway of AMPK showed no alteration of their activities by overall 
exercise effect. It might occur due to a bout of exercise with the same intensity and duration as 
the training protocol before sacrifice. In fact, it has been reported that acute exercise enhanced 
AMPK activities in skeletal muscle 302. 
Adaptation in skeletal muscle includes the modulation of several transcriptional factors 
in response to mitochondrial metabolism to promote lipid consumption as an energy source 303. 
Specifically, PGC-1α acts as a key regulator in these transcriptional alterations, which regulates 
mitochondrial and fatty acid metabolism 304. In these metabolic events, SIRT1 contributes to the 
deacetylation of PGC-1α, and in turn controls its activity 305. In the same context, our data showed 
that CLA supplementation activated SIRT1 expression in skeletal muscle, and up-regulated PGC-
1α (Fig. 7.3E and 7.3F). However, further studies are required to investigate how SIRT1 is 
activated by CLA. 
Mitochondrial biogenesis is a complex process that increases volume and changes 
mitochondrial composition in response to physical and nutritional stimuli 219. Activated PGC-1α 
triggers the modulation of nuclear and mitochondrial regulators such as PPARδ, NRF-1 and -2, 
and Tfam, which are intimately linked to the stimulation of mitochondrial biogenesis 10. In the 
current study, CLA supplementation sequentially facilitated PGC-1α, PPARδ and PGC-1α-NRF-
1-Tfam signaling cascades. Therefore, it suggests that CLA may potentiate mitochondrial 
biogenesis. Although this study demonstrated the alteration in the biochemical markers of 
mitochondrial biogenesis, it did not include a histological analysis, such as a visualization of 
fluorescent mitochondria using dyes and microscopy, as well as the number of mitochondrial 
DNA copies 228. Thus, further studies are needed in order to better understand the underlying 
morphological changes of how CLA regulates mitochondrial biogenesis.  
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Along with PGC-1α, one of the key regulators in mitochondrial biogenesis and muscle 
fiber type transformation is PPARδ. It is evident that PPARδ in skeletal muscle increases 
mitochondria-rich oxidative type I fiber 3,191,192. In regards to skeletal muscle fibers, they are 
briefly categorized into slow-twitch and fast-twitch, depending on their contractile properties 188. 
The fiber in humans consists of myosin heavy chains (MHCs), which are segmented into MHC I, 
MHC IIa and MHC IIx/d. These MHC isoforms have different characteristics: MHC I is an 
oxidative slow-twitch type I fiber with a high density of mitochondria, which uses fatty acids as 
the primary energy source; MHC IIx/d is a glycolytic fast-twitch type II fiber, using glucose and 
phosphocreatine primarily to generate energy; MHC IIa is likely between type I and IIx/d 189. As 
shown in the previous study 192, PPARδ could affect the regulation of muscle fiber type, 
contributing to prolonged running endurance. In the present study, CLA-fed mice led to an 
increase of PPARδ expression and the induction of overall MHC genes. Furthermore, CLA 
supplementation significantly increased the gastrocnemius muscle mass (Table 7.2). Thus, it 
suggests that CLA supplementation could affect the overall physiology of skeletal muscle based 
on the PPARδ-driven metabolic events. 
In regards to lipid metabolism, free fatty acids in plasma pass through a plasma 
membrane in skeletal muscle by diffusion, or by transportation using receptor proteins such as 
cluster of differentiation 36 (CD36), fatty acid binding protein (Fabp) and fatty acid transporter 
protein 1 (FATP1), which in turn forms fatty acyl-CoA complexes. Subsequently, they enter 
mitochondria by shuttling through CPT1 and then undergo oxidation 306. Our data demonstrated 
that CLA significantly increased three key genes associated with lipid metabolism in skeletal 
muscle, especially LPL, PPARα and CPT1β, which is consistent with the previous studies in mice 
17,18,27,36,63,149
. Particularly, two studies among these elucidated to the effects of CLA 
supplementation combined with endurance training on the alteration of molecular markers in 
skeletal muscle lipid metabolism 18,149. Intriguingly, a number of transcriptional factors to control 
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lipid metabolism are regulated by PPARδ in skeletal muscle, resulting in increased fatty acid β-
oxidation 257.  
Furthermore, PPARδ targets genes in glucose and insulin metabolism. Increased PPARδ 
induces phosphorylation of PDK, leading to the negative regulation of pyruvate dehydrogenase 
complex (PDC). As a consequence, carbohydrate oxidation is reduced during fasting 193 . 
However, results from the current study did not observe the overall effects of CLA or exercise in 
PDK4 expression, although PPARδ protein levels were increased by CLA supplementation. Parra 
et al.198 reported that CLA supplementation did not increase mRNA levels of PDK4, as well as 
other genes associated with glucose and insulin metabolism. Increased GLUT4 expression in this 
study is consistent with the previous observations 17,33,63. Therefore, our data suggest that CLA 
supplementation may not inhibit glucose and insulin metabolism, but may promote lipid 
metabolism.  
Overall, CLA supplementation led to enhanced endurance capacity and positively 
altered molecular markers in skeletal muscle metabolism, whereas exercise effects were limited 
in this study. It might be derived from the heterogeneous factors in terms of the exercise protocols 
such as intensity and duration. Although overall endurance exercise is known to induce 
mitochondrial biogenesis and muscle fiber type transformation via the modulation of intracellular 
biomarkers, it is not completely understood how the magnitude of exercise intensity and duration 
influences these physiological and phenotypic alterations in skeletal muscle 307. In fact, Tadashi et 
al.308 reported that PGC-1α expression levels were significantly correlated with the intensity of 
running endurance in mice. In our study, we used a mixture of low-intensity and low-volume as 
an exercise protocol. Thus, it could be suggested that increased endurance capacity under low 
levels of exercise intensity and duration relies on CLA supplementation rather than exercise.  
The potential health concerns related to CLA supplementation to date are glucose 
intolerance and fatty liver 13,270,271. In the present study, we could not find any evidence in terms 
of glucose intolerance associated with CLA supplementation. In fact, no significant increases in 
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serum glucose levels were observed. However, more studies like glucose tolerance tests are 
needed to confirm the influence of CLA in glucose intolerance. As reported in previous studies 
17,18,152
, we observed an enlarged liver after CLA supplementation. It can be suggested that CLA 
dramatically affects lipid metabolism, including reduced adipose tissue and increased hepatic 
lipogenesis, resulting in the accumulation of TG in the liver. In the same context, the current 
results showed decreased adipose tissue weight and serum TG levels in the CLA supplemented 
mice (Table 7.2 and 7.3). Moreover, previous studies in rodents demonstrated no pathological 
significance in the hepatic markers 269,295.  
 In conclusion, we demonstrated that CLA supplementation, yet not exercise alone, 
promotes endurance capacity and increases skeletal muscle mass in this mouse model. It implies 
that CLA supplementation is involved in skeletal muscle metabolism by stimulating 
mitochondrial biogenesis and inducing muscle fiber gene expression, resulting in increased lipid 
metabolism. Particularly, enhanced PPARδ-mediated signaling pathways regulate these metabolic 
events. Although the precise mechanism of whether CLA regulates PPARδ directly or indirectly 
was not dealt with this study, it is suggested that CLA exerts its action via the activation of PGC-
1α through SIRT1, subsequently leading to the up-regulation of PPARδ and its related target 
markers in skeletal muscle. If further research on CLA supplementation is combined with an 
appropriate exercise regime, with intensity and duration, it may provide a more effective method 
to prevent obesity by the modulation of skeletal muscle metabolism. 
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CHAPTER 8 
CONCLUDING REMARKS 
 
 To date, calorie restriction and exercise are the most effective strategies to prevent 
and/or reduce incidences of obesity. Nonetheless, there is an increasing prevalence of obesity due 
to physical inactivity and sedentary lifestyle. Thus, various studies have been trying to find more 
efficient prevention and treatment for obesity by understating the determinants contributing to 
skeletal muscle and physical activity.  
It is known that CLA reduces body fat and increases lean mass, resulting in the 
alteration of body composition. While it is well established that CLA attenuates body fat 
accumulation through the regulation of metabolism in adipocytes, the mechanisms of CLA on 
skeletal muscle metabolism are not yet fully known. The objective of this proposed research was 
to discover the underlying mechanism of how CLA modulates metabolism in skeletal muscle 
based on the AMPK signaling pathway, and subsequent downstream signaling cascades.  
 In C2C12 murine skeletal muscle cells, both active CLA isomers (cis-9,trans-11 and 
trans-10,cis-12) significantly activated PGC-1α, a master regulator of mitochondrial biogenesis, 
via AMPKα phosphorylation in an isomer-specific manner. Subsequently, CLA isomers 
enhanced PPARδ, NRF-1 and Tfam, which was needed to regulate mitochondrial biogenesis. 
Consequently, CLA isomers increased the number of copies of mitochondrial DNA, mirrored by 
enhanced mitochondrial biogenesis. It was suggested that CLA might act as an activator of 
mitochondrial biogenesis in skeletal muscle. 
 In the genetically induced inactivity adult-onset obesity model (Nhlh2 gene knockout 
mice), CLA supplementation prevented body weight gain and fat accretion by improved physical 
activity. Specifically, CLA enhanced voluntary movement and increased skeletal muscle mass. It 
is implied that CLA induced the physiological changes in skeletal muscle, supporting the 
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activation of AMPKα, PGC-1α and downstream biomarkers related to mitochondrial biogenesis, 
such as PPARδ and Tfam in CLA-fed mice. Thus, it might indicate that CLA treatment during the 
developmental period in mice had a preventive effect on obesity caused by physical inactivity.  
 Next, we demonstrated that post-weaning CLA supplementation contributed to the 
reduction of voluntary activity and glucose intolerance using the CLA withdrawal model in the 
high-fat fed Nhlh2 mice. Although the genetically obese mice were not sufficient per se to 
maintain health benefits by CLA supplementation during the pre-obese state, normal mice 
showed significantly decreased body weight gain and fat mass along with increased physical 
activity throughout the experiment. In particular, CLA-fed mice after withdrawal had improved 
glucose homeostasis. These alterations in normal mice might be derived from the upregulation of 
AMPKα and PPARδ, as well as the desensitization of PTEN and the sensitization of AKT at 
threonine 308 in skeletal muscle. Thus, it could be suggested that the post-weaning administration 
of CLA during the pre-obese state might partially stimulate the underlying molecular targets 
involved in muscle metabolism in normal mice, yet not in the genetically induced inactive adult-
onset animal model.  
 Lastly, we elucidated to the effects of CLA supplementation and/or endurance exercise 
on skeletal muscle metabolism. Results from this study demonstrated that CLA, but not low-
levels of exercise alone, promoted the maximum running time and distance along with increased 
skeletal muscle mass. In addition, CLA supplementation stimulated mitochondrial biogenesis-
related factors through the activation of SIRT1 and PGC-1α in skeletal muscle. Of particular 
importance, CLA increased the expression levels of PPARδ which is a key regulator of muscle 
fiber type transformation. Consequently, CLA induced these molecular events such as 
mitochondrial biogenesis and upregulated genes in muscle fibers, resulting in increased lipid 
metabolism in skeletal muscle. It implied that CLA exerted its actions via the PPARδ-mediated 
signaling pathway.  
Collectively, CLA potentially acts as an exercise-mimetic, resulting in improved 
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physical activity, which can support its function of regulating body fat. 
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